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1,5- AG     1,5- anhydroglucitol  217 
1-h PG     1-hour plasma glucose  218 
2-h PG     2-hour plasma glucose 219 
aROC   Area under the Receiver-Operating Characteristic curves 220 
ADA       American Diabetes Association 221 
ALT                Alanine Aminotransferase 222 
BCAA     Branched-Chain Amino Acids  223 
BMI      Body Mass Index 224 
CGM      Continuous Glucose Monitoring 225 
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FPG        Fasting Plasma Glucose 230 
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SMBG     Self-Monitoring of Blood Glucose  246 
SI                    Insulin Sensitivity 247 
T1D         Type 1 Diabetes Mellitus 248 
T2D         Type 2 Diabetes Mellitus 249 
UKPDS    United Kingdom Prospective Diabetes Study  250 
WHO      World Health Organization  251 








 A 1-hour plasma glucose (1-h PG) threshold >155 mg/dl (8.6 mmol/L) during an oral 258 
glucose tolerance test (OGTT) may be a suitable biomarker for identifying normal glucose 259 
tolerant (NGT) individuals at risk for future type 2 diabetes (T2D).  260 
 A one-hour, non-fasting, 50g Glucose Challenge Test (GCT) performed during a routine 261 
health care visit has potential for practical screening of glucose disorders. 262 
 The shape of the glucose curve reflects the cumulative effect of insulin sensitivity and 263 
response on glucose concentrations with prospective studies warranted to evaluate its 264 
prognostic utility. 265 
 The continuous glucose monitor (CGM) has facilitated insight into the pathophysiology of 266 
prediabetes and phenotypes of T2D and holds promise for detecting glycemic disorders. 267 
 Metabolomic profiling including amino acids, lipids, carbohydrates and other metabolites 268 
may be useful for early diagnosis of glycemic disorders.  269 
 Non-classical markers for assessing glycemic disorders including fructosamine, glycated 270 
albumin, and 1,5-anhydroglucitol that evaluate shorter periods of glucose exposure than 271 










Prediabetes (intermediate hyperglycemia) consists of two abnormalities, impaired fasting glucose 280 
(IFG) and impaired glucose tolerance (IGT) detected by a standardized 75-gram oral glucose 281 
tolerance test (OGTT). Individuals with isolated IGT or combined IFG and IGT have increased 282 
risk for developing type 2 diabetes (T2D) and cardiovascular disease (CVD). Diagnosing 283 
prediabetes early and accurately is critical in order to refer high-risk individuals for intensive 284 
lifestyle modification. However, there is currently no international consensus for diagnosing 285 
prediabetes with HbA1c or glucose measurements based upon American Diabetes Association 286 
(ADA) and the World Health Organization (WHO) criteria that identify different populations at 287 
risk for progressing to diabetes. Various caveats affecting the accuracy of interpreting the HbA1c 288 
including genetics complicate this further. This review describes established methods for 289 
detecting glucose disorders based upon glucose and HbA1c parameters as well as novel 290 
approaches including the 1-hour plasma glucose (1-h PG), glucose challenge test (GCT), shape 291 
of the glucose curve, genetics, continuous glucose monitoring (CGM), measures of insulin 292 
secretion and sensitivity, metabolomics, and ancillary tools such as fructosamine, glycated 293 
albumin (GA), 1,5- anhydroglucitol (1,5-AG).  Of the approaches considered, the 1-h PG has 294 
considerable potential as a biomarker for detecting glucose disorders if confirmed by additional 295 
data including health economic analysis. Whether the 1-h OGTT is superior to genetics and 296 
omics in providing greater precision for individualized treatment requires further investigation. 297 
These methods will need to demonstrate substantially superiority to simpler tools for detecting 298 






Keywords: prediabetes, type 2 diabetes, HbA1c, glycemic variability, biomarkers, oral glucose 303 
tolerance test, continuous glucose monitoring, metabolomics, cardiovascular disease.  304 
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1. Introduction 391 
Prediabetes (intermediate hyperglycemia), a condition that can precede the development of type 392 
2 diabetes (T2D) by many years, is defined by blood glucose levels that are higher than normal 393 
but below established threshold criteria defining diabetes. In 2017, an estimated 7.3% (352 394 
million adults) of the global population had prediabetes, a figure expected to rise to 8.3% (587 395 
million adults) by the year 2045 [1].  396 
 397 
Prediabetes consists of two abnormalities, impaired fasting glucose (IFG) and impaired glucose 398 
tolerance (IGT), the latter detected by a standardized 75-gram oral glucose tolerance test 399 
(OGTT). Accurately diagnosing prediabetes is critical so that high-risk individuals can be 400 
referred for lifestyle intervention to prevent progression to T2D and associated complications. 401 
Glucose and HbA1c diagnostic criteria for prediabetes proposed by the American Diabetes 402 
Association (ADA) and the World Health Organization (WHO) differ in their sensitivities and 403 
specificities [2] identifying, therefore, different populations at risk for progressing to diabetes.  404 
Furthermore, as there are currently five distinct definitions for prediabetes, an international 405 
consensus would benefit the development of unambiguous and evidence-based criteria [3]. 406 
Differences in genetics and the glycation gap affecting the accuracy of HbA1c levels complicate 407 
this further [4, 5]. The risk of future T2D and cardiovascular disease (CVD) is continuous along 408 
the spectrum of 1- and 2-hour plasma glucose (1-h PG, 2-h PG) and HbA1c values. Although 409 
inevitably any cut-point will be arbitrary, the goal remains to identify with greater accuracy those 410 




This review will consider established diagnostic methods based on glucose and HbA1c 413 
parameters as well as alternative approaches. These include the 1-h PG, the Glucose Challenge 414 
Test  (GCT), the shape of the glucose curve, genetic testing, continuous glucose monitoring 415 
(CGM) with assessment of glycemic variability (GV), measurements of insulin secretion and 416 
insulin sensitivity, metabolomics and ancillary tools such  as fructosamine, glycated albumin 417 
(GA), 1,5-anhydroglucitol (1,5-AG).  While these approaches have broadened insight into the 418 
pathophysiology and mechanisms underlying glucose disorders, in many instances, their 419 
complexity and expense likely make their use impractical and thus remain research tools.  420 
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2. Diagnosing Type 2 Diabetes 421 
T2D is a disorder of impaired glucose homeostasis with the diagnosis based upon three different 422 
measurements: fasting plasma glucose (FPG), 2-hour plasma glucose (2-h PG) after a 75-gram 423 
glucose load, and HbA1c. Each provides vital information about glucose metabolism and reflects 424 
different physiological mechanisms. The FPG reflects glucose homeostasis in the post-absorptive 425 
state while the 2-h PG primarily reflects disposal of an exogenous glucose load [6]. The HbA1c 426 
correlates strongly with overall glycemia as it reflects the average glucose over 2-3 months. The 427 
FPG strongly correlates with HbA1c in the non-diabetic range as elevations in the FPG 428 
concentration are present throughout the day. In contrast, post-prandial hyperglycemic 429 
excursions are transient, occurring 3-4 hours after each meal, while 2-h PG are more strongly 430 
associated with elevations in HbA1c with increasing overall glycemia. Therefore, it is not 431 
surprising that the HbA1c has a stronger correlation with the FPG than the 2-h PG [7-10]. 432 
2.1. Fasting Plasma Glucose and Diagnosis of T2D 433 
Before 1997, diabetes was diagnosed based on a FPG concentration >140 mg/dl (7.8 mmol/L) 434 
which was arbitrarily determined to represent the upper limit of normal FPG. In 1997, the ADA 435 
Expert Committee [11] revised the criteria for diagnosing diabetes [12] reducing the FPG cut-436 
point for diabetes from 140 mg/dl (7.8 mmol/L) to 126 mg/dl (7.0 mmol/L) and retained the 2-h 437 
PG cut-point >200 mg/dl (11.1 mmol/L). The revised  FPG concentration threshold was based 438 
upon three different studies [11, 13, 14] which demonstrated that the risk of proliferative diabetic 439 
retinopathy increased significantly when the FPG exceeded 126 mg/dl (7.0 mmol/L) and the 2-h 440 
PG was >200 mg/dl(11.1 mmol/L). The ADA Expert Committee reasoned that if a complication 441 
of the disease was present at a FPG ≥126 mg/dl (7.0 mmol/L), then the disease, i.e. diabetes, 442 
must exist.  443 
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2.2. 2-hour Plasma Glucose and Microvascular Disease 444 
Microvascular end-points (retinopathy and microalbuminuria)  have been essential for defining 445 
glycemic thresholds and developing current diagnostic criteria. In a study of 960 Pima Indians, 446 
diabetic retinopathy (microaneurysms or hemorrhages) was largely confined to a 2-h PG level ≥ 447 
240 mg/dl (13.33 mmol/L) rather than a 2-h PG level < 200 mg/dl (11.11 mmol/L). A previous 448 
investigation in this population  identified found 252 mg/dl (14 mmol/L) optimal for diagnosing 449 
retinopathy [15].Threshold values of 2-h PG for retinopathy ranged from 194 mg/dl (10.8 450 
mmol/L) [11] to 198 mg/dl (11 mmol/L) in Japanese  [16], 218 mg/dl  (12.1 mmol/L) in 451 
Egyptian [14] , and 236 mg/dl (13.1 mmol/L) in Australian populations [17]. Therefore, the 452 
current 2-h PG diagnostic threshold represents a reasonable compromise replicated in other 453 
studies [18, 19]. A more recent investigation of nine pooled studies in a multiethnic population 454 
of 21,334 participants from 5 countries with 2-h PG and diabetic-specific retinopathy 455 
demonstrated that  a 2-h PG of 234 mg/dl (13.0 mmol/L) was optimal for identifying moderate or 456 
severe non-proliferative diabetic retinopathy [20]. It is worth mentioning that isolated 457 
retinopathy is also common in individuals without diabetes and, furthermore, the risk of 458 
diabetes-specific retinopathy varies with ethnicity [21].  459 
 460 
The 2-h PG threshold value predictive of microalbuminuria and diabetic nephropathy has been 461 
investigated less extensively. The percentage of individuals in a Pima Indian population with 462 
nephropathy (protein to creatinine ratio ≥1.0 g:g) was 1.6% in the group with 2-h PG < 227 463 
mg/dl (12.6 mmol/L) and 6.2% in those with higher levels  while the 5-year incidence was 1.2% 464 
and 3.6%, respectively [13]. In the 2,182 participants of the Australian Diabetes Obesity and 465 
Lifestyle study, unlike retinopathy, the 2-h PG showed no evidence of a threshold effect [17]. 466 
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Nevertheless, in the 3,644 adults enrolled in the 2005-2014 National Health and Nutrition 467 
Examination Survey (NHANES) with prediabetes based on HbA1c and FPG levels, the adjusted 468 
odds ratio (95% confidence interval) was 2.05 (95%CI 1.33-3.14) for albuminuria  (albumin ⩾30 469 
mg/g of creatinine)  associated with a 2-h PG ≥ 200 mg/dl (11.1 mmol/L) [22]. The current 470 
diagnostic cut-point of 200 mg/dl (11.1 mmol/L) therefore represents a threshold beyond which 471 
the risks of retinopathy and, in general, microvascular diseases rise.  472 
2.3. HbA1c and Diagnosis of T2D 473 
Due to limitations in measuring the FPG and 2-h PG (Table 1), an International Expert 474 
Committee (IEC) in 2009 recommended HbA1c for diagnosing diabetes [23] which was 475 
endorsed by the ADA [24] (Table 1). The HbA1c measurement is standardized worldwide and 476 
quality assurance tests are in place [25]. Nonetheless, the use of HbA1c for diabetes diagnosis 477 
has certain limitations that raise concerns about its use as the sole method for diabetes diagnosis 478 
(Table 1).   479 
HbA1c increases with age independent of glucose tolerance [26-31] and is affected by ethnicity 480 
[32-38] and genetic factors [39, 40]. Data from NHANES [27] have demonstrated that the 481 
relationship between HbA1c and plasma glucose concentrations (both fasting and 2-h PG) is 482 
shifted to the right in African Americans, compared to Mexican Americans and non-Hispanic 483 
white subjects, having an approximately 0.65% higher level than Caucasians [27] under 484 
comparable glucose conditions. Because of the narrow non-diabetic HbA1c range, the influence 485 
of ethnicity can significantly affect the classification of subjects. 486 
Genetic makeup also affects the HbA1c level independent of PG concentration [39-41]. Thus, 487 
relying solely on the HbA1c to diagnose diabetes can result in approximately 650,000 missed 488 
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cases of diabetes in the US alone. These factors should therefore be taken into account when 489 
T2D is diagnosed based strictly upon HbA1c levels [42-44]. 490 
2.3.1. HbA1c Cut-Point to Diagnose T2D 491 
Similar to glucose, the deterioration in glucose homeostasis in relation to HbA1c follows a 492 
continuum, presenting a challenge when determining the HbA1c cut-point for diagnosing 493 
diabetes. The IEC has set the HbA1c  ≥ 6.5% (48 mmol/mol) as the cut-point for the diagnosis of 494 
diabetes [23]. This decision was based on the DETECT-2 study [20] examining pooled data from 495 
44,623 patients in 12 different studies which found that the incidence of proliferative diabetic 496 
retinopathy increased significantly at this threshold. However, this threshold has not been 497 
consistently found so caution should be exercised when using HbA1c alone as the diagnostic 498 
criteria for diabetes (31, 59-63, 64, 65).   499 
2.3.2. Diabetes Diagnosis:  HbA1c versus Glucose Criteria 500 
The cut-point for the diagnosis of T2D with both HbA1c and glucose criteria is based upon the 501 
threshold for development of retinopathy. However, studies examining their concordance 502 
revealed significant disagreement. Glucose criteria, especially the 2-h PG, have greater 503 
sensitivity than HbA1c in diagnosing diabetes in the majority of cohorts [27, 28, 45-51] each 504 
diagnosing distinct patient populations. 505 
In cross-sectional data from 5,395 nondiabetic participants in NHANES (2005-2010), the 506 
number of subjects diagnosed with diabetes by glucose criteria was more than double than those 507 
identified with HbA1c criteria (5.7% versus 2.23%) [45]. Thus, the sensitivity of HbA1c criteria 508 
(HbA1c >6.5%; 48 mmol/mol)) was only 41%, although it had 99% specificity in identifying 509 
subjects with diabetes diagnosed by glucose criteria. Other studies have similarly demonstrated 510 
17 
 
low sensitivity (20-40%) and high specificity of HbA1c criteria [28, 47-49, 51, 52].  The 511 
sensitivity of HbA1c in detecting patients with diabetes varies amongst ethnic groups [32, 36, 53, 512 
54] being higher in Chinese [53], Asian Indian (75), and African populations [55] than in 513 
Caucasians. When viewed collectively, data suggest that a HbA1c <6.5% (48 mmol/mol) does 514 
not exclude the presence of diabetes. Thus, a HbA1c threshold of 6.5% (48 mmol/mol) for 515 
diagnosing diabetes may leave many undiagnosed (i.e. high false negative rate) and untreated 516 
despite having increased risk of microvascular complications according to glucose criteria.  517 
In clinical practice, obtaining simultaneous FPG and HbA1c measurements is convenient as 518 
diabetes screening is primarily performed using a single fasting blood sample. Given the partial 519 
overlap between HbA1c and FPG, measuring both will increase the likelihood of identifying 520 
diabetes [53, 54, 56].  The combination of HbA1c > 6.5% (48 mmol/mol) and/or FPG >126 521 
mg/dl (7.0 mmol/L) identifies >85% of patients with T2D in Chinese (69) and Asian Indian (71) 522 
populations. Likewise, the combination of FPG and HbA1c has been shown to identify 80% of 523 
patients with diabetes [9] in a Korean population although the optimal cut-point for FPG and 524 
HbA1c in this study was 100 mg/dl (5.6 mmol/L) and 5.5% (37 mmol/mol), respectively.  525 
Using the FPG and HbA1c alone for the diagnosis of diabetes will primarily miss subjects with 526 
isolated postprandial hyperglycemia. The risk of microvascular risk in this population, 527 
constituting approximately 20% of those with T2D, has not been examined. Moreover, the 2-h 528 
PG has a stronger association with the incidence of CVD, the major cause of death in T2D. 529 
NHANES (2005-2014) [22] demonstrated that 6.9% and 8.2% of individuals respectively 530 
diagnosed as having prediabetes and NGT with the FPG and HbA1c, had T2D with a 2-h PG 531 
>200 mg/dl (11.1 mmol/L). Those diagnosed with T2D by an isolated 2-h PG had significantly 532 
higher rates of hypertension, dyslipidemia (low HDL and high triglycerides), microalbuminuria 533 
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and elevated alanine aminotransferase (ALT). Thus, measuring a FPG and HbA1c alone without 534 
a 2-h PG will preclude identifying those at high risk for CVD [22, 57].  535 
3. Diagnosing Prediabetes 536 
3.1. Fasting Plasma Glucose and Prediabetes – IFG 537 
The ADA Expert Committee introduced IFG (FPG=110-125 mg/dl [6.1 -6.9 mmol/L]) in 1997 538 
(77) as a “prediabetes” condition overcoming limitations in diagnosing IGT (Table 1).The  IFG 539 
designation was intended to identify individuals with IGT without an OGTT although subsequent 540 
studies demonstrated that it had a low sensitivity for this purpose. Furthermore, as IFG identifies 541 
a distinct population [58, 59],  the threshold was reduced to 100 mg/dl (5.6 mmol/L) making its 542 
predictive value comparable to IGT [60].  543 
IFG is pathophysiologically distinct from IGT [58, 61]. Isolated IFG may confer similar risk for 544 
conversion to T2D (~5 fold) as isolated IGT [59] although this is not uniformly agreed upon as 545 
will be seen below. The relative risk progressively increases with the FPG, steeply increasing 546 
within the IFG range [59]. However, it is not clear whether the increase in FPG confers risk for 547 
diabetes independently or if this is secondary to its strong correlation with the 1-h and 2-h PG 548 
level (81). When participants with IFG and NGT are matched for 1-h PG levels, the risk for T2D 549 
is similar  indicating that the contribution of FPG is small and primarily due to the increase in the 550 
1-h PG. Individuals with both IFG and IGT have double the risk of T2D compared to either 551 
isolated IFG or IGT [59, 62]. Finally, IFG does not confer an elevated risk of CVD [63] .  552 
3.2. 2-Hour Plasma Glucose and Prediabetes- IGT 553 
The National Diabetes Data Group created the term IGT in 1979 defined by a 2-h PG = 140-199 554 
mg/dl (7.8-11.1 mmol/L) [12]. Individuals with IGT manifest elevated future risk of T2D with 555 
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the annual progression rate varying with ethnicity from 5-11%.  However, IGT does not always 556 
progress to T2D, the lifelong future risk of T2D approximating 50%. Moreover, as IGT 557 
constitutes approximately 40% of all subjects progressing to T2D,individuals may progress to 558 
T2D in the absence of IGT. As already noted, individuals with both IFG and IGT have twice the 559 
risk of developing T2D and as discussed in greater detail below, unlike IFG, IGT is associated 560 
with elevated cardiovascular risk (84). 561 
 562 
3.3. HbA1c and Diagnosis of Prediabetes  563 
HbA1c was recommended for diagnosing prediabetes to address limitations associated with 564 
glucose measurements (Table 1). However, both cross-sectional and longitudinal studies 565 
comparing HbA1c with glucose criteria (i.e. IFG and/or IGT) demonstrated that the latter 566 
outperformed HbA1c and captured twice the number of subjects progressing to T2D. Similar to 567 
FPG, the future risk of T2D increases continuously with the HbA1c level with no threshold 568 
above which diabetes risk increases. Thus, determining the HbA1c range for prediabetes is 569 
challenging. The International Expert Committee (IEC) recommended [23] that an HbA1c = 570 
6.0% - 6.4% (42-46 mmol/mol) identified high-risk individuals with prediabetes whereas this 571 
cut-point was later lowered by the ADA to 5.7% (39 mmol/mol) [24] with HbA1c=5.7-6.4% (39-572 
46 mmol/mol), the current range for diagnosing prediabetes. 573 
NHANES 2005-2006 [27] and 2011-2014 [64] demonstrated that the prevalence of prediabetes 574 
with HbA1c =5.7-6.4% (39-46 mmol/mol)) was significantly less than when diagnosed by an 575 
OGTT. Although the relative risk of progression to T2D is similar whether prediabetes is 576 
diagnosed by HbA1c or glucose criteria, the absolute number is higher when diagnosed with 577 
glucose criteria [65].   578 
20 
 
To understand the pitfalls of relying exclusively on HbA1c, it is important to note that β-cell 579 
failure is primarily responsible for deterioration of glucose tolerance. However, as HbA1c is 580 
insensitive for identifying individuals with early impairment in β-cell function, its isolated use 581 
will classify a large number of high-risk individuals as normal. This point is exemplified  in a 582 
high-risk population of Mexican Americans in whom β-cell function in those with NGT and 583 
HbA1c < 5.7%  was comparable to NGT subjects with HbA1c = 5.7–6.4% [66]. Notably, 584 
participants with IFG or IGT had a marked decrease in β-cell function independent of the HbA1c 585 
level. Therefore, utilizing an OGTT is preferable for identifying individuals with early β-cell 586 
dysfunction who are at increased future risk for T2D.  Finally, although HbA1c alone is a weaker 587 
predictor of future risk for T2D compared with the 1-h PG (see below), it provides additive 588 
information when combined with established prediction models (88). 589 
3.4. 1-hour Plasma Glucose  590 
3.4.1. Early Biomarker of Dysglycemia 591 
The 1-h PG during the 75-gram OGTT appears to be a useful early biomarker of dysglycemia 592 
[67, 68]. A cut-off of 155 mg/dl (8.6 mmol/L) was initially identified in the San Antonio Heart 593 
Study (SAHS) based on the greater predictive power of the 1-h PG for future T2D compared 594 
with fasting and 2-h PG determined by the aROC curve method [69].  Evaluation of fourteen 595 
OGTT glucose-derived indices in two longitudinal studies, the Botnia and the Malmö Prevention 596 
Project (MPP) cohorts, demonstrated that the 1-h PG was the best predictor for mid- and long-597 
term incident T2D in middle-aged European adults with NGT [70]. Moreover, the 1-h PG in a 598 
German cohort had higher predictive power comparing the aROC curves for future T2D with 599 
FPG, 2-h PG, and HbA1c (aROC 0.70, 0.84, 0.79, and 0.73 for  FPG, 1-h PG, 2-h PG, and 600 
HbA1c, respectively) [71]. These results were confirmed in different ethnic groups including 601 
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Mexican Americans, Japanese, Han Chinese, Korean, Southwestern Native American, and Asian 602 
Indian adults (Table 3) [72-76]. Notably, the Botnia Prospective Study cohort demonstrated that 603 
the 1-h PG outperformed fasting and 2-h PG levels in predicting progression to T2D either alone 604 
or in combination with six metabolic markers including glucose, mannose, a-hydroxybutyrate, α-605 
tocopherol, bradykinin-hydroxyproline, and the unknown metabolite X-12063 [77]. The 606 
predictive power of the 1-h PG for T2D in various cohorts is summarized in Table 3 and Table 4 607 
comparing the AUC of FPG, 1-h PG, and 2-h PG for predicting T2D. Several longitudinal 608 
studies have confirmed that those with NGT and a 1-h PG value > 155 mg/dl (>8.6 mmol/L) 609 
were at increased risk for T2D [69, 78-83]. A meta-analysis of six prospective studies 610 
demonstrated the greater risk of progression [OR 4.33, 95% CI 3.40 to 5.51]) [67]. Moreover, 611 
individuals with IFG and/or IGT and a 1-h PG > 155 mg/dl (8.6 mmol/L) have a 2-5fold greater 612 
future risk of T2D.  613 
Studies exploring pathophysiological mechanisms have shown that individuals with NGT and a 614 
1-h PG > 155 mg/dl (8.6mmol/L) share several abnormalities observed in IGT including 615 
impaired insulin sensitivity, β-cell dysfunction, β-cell glucose sensitivity, and reduced insulin 616 
clearance [81, 84-94]. Another pathophysiologic defect linked to excessive excursions of 1-h PG 617 
in subjects with NGT is increased intestinal glucose absorption. T2D has been associated with 618 
increased intestinal glucose uptake [95-98] and accelerated absorption playing a role in excessive 619 
post-load glucose excursions [99-101]. The latter is dependent on gastric emptying and duodenal 620 
abundance of the glucose carrier sodium/glucose co-transporter 1 (SGLT-1) and glucose 621 
transporter 2 (GLUT-2) [99, 102, 103] both of which are increased in T2D [98]. In subjects 622 
undergoing upper endoscopy, duodenal expression of SGLT-1, but not GLUT-2, was increased 623 
significantly in those with NGT and 1-h PG > 155 mg/dl (8.6 mmol/L) as well as IGT [100].  624 
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However, a positive relationship was not observed between duodenal SGLT-1 expression with 625 
fasting or 2-h PG levels suggesting that accelerated glucose absorption in determining early post-626 
prandial hyperglycemia is related to increased expression of duodenal SGTL-1 [100]. These 627 
observations were subsequently confirmed by a study showing enhanced rate of oral glucose 628 
absorption, measured by labelled OGTT, in those with 1-h PG ≥ 155 mg/dl (8.6 mmol/L) but not 629 
the 2-h PG [101].  630 
The frequency of subjects with NGT and elevated 1-h PG varies based on study design ranging 631 
from 11% to 16% in population-based studies, to 25% to 42% in cohorts enriched for high-risk 632 
subjects [67]. It is noteworthy that the frequency of individuals with 1-h PG level  > 155 mg/dl 633 
(8.6 mmol/L) increases as glucose tolerance deteriorates with 56.6% in individuals with isolated 634 
IFG, 77.6% in individuals with isolated IGT, and 93.8% in those with combined IFG + IGT, and 635 
98.8% in subjects with newly diagnosed T2D. These data suggest that a 1-h post-load PG level > 636 
155 mg/dl (8.6 mmol/L) may be an earlier biomarker of dysglycemia than IGT in the lengthy 637 
trajectory from prediabetes to T2D. Furthermore, as the progression from NGT to IGT follows a 638 
continuum, there is no absolute threshold value for determining risk. For example, in the RISC 639 
cohort, the 1-h PG of 155 mg/dl (8.6mmol/L) was the most practical capturing 22% of the 640 
population compared with other cut-off values. A threshold of 137 mg/dl (7.6mmol/L) 641 
corresponded to 38% of the population with NGT whereas a cut-off value of 114 mg/dl (6.32 642 
mmol/L) would identify 66% of the population [83].   643 
 644 
A health economic analysis is important to determine the acceptability of the 1-h PG in clinical 645 
practice. Although there is a need for a formal technical health assessment, simulation of benefits 646 
from the 1-h PG as a classification tool in the Finnish population demonstrated improved quality 647 
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of life, increased life expectancy and considerable cost savings. Alyass et al therefore concluded 648 
that the 1-h PG could have benefit in Finland as well as globally [70, 104].  649 
 650 
3.4.2. Predictor of Complications and Adverse Outcomes 651 
The 1-h PG  is an independent risk factor for micro- and macrovascular complications as well as 652 
mortality [82, 105-108]  possibly explained by its association with a pro-atherogenic risk profile 653 
[109] and several cardiovascular risk factors including thrombosis, endothelial dysfunction, 654 
oxidative stress, worse lipid profile, increased blood pressure, inflammatory markers, and uric 655 
acid (162). Furthermore, the 1-h PG correlates with increased arterial stiffness, carotid intima-656 
media thickness, increased left ventricular mass and left ventricular diastolic dysfunction (162). 657 
The combination of an elevated 1-h PG and IGT resulted in higher risk for T2D, micro- and 658 
macrovascular risk as well as mortality suggesting that individuals at high-risk should be 659 
diagnosed before progressing to IGT (137,140). 660 
3.4.3. Reproducibility 661 
Briker et al studied the reproducibility of the 1-h PG ≥ 155 mg/dl (8.6 mmol/L) in 119 subjects 662 
with repeat OGTT in the Africans in America Study [110] and found it equivalent to fasting and 663 
2-h PG levels. Additional reproducibility data from a larger cohort in well-designed trials would 664 
be of interest. 665 
 666 
 667 
4.  Genetic Testing and Risk Prediction of T2D 668 
Attempts to predict T2D with genetic tests have thus far been unsuccessful. Prior to the genome-669 
wide association studies (GWAS) era, three genetic variants in KCNJ, PPARG and TCF7L2 670 
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genes were associated with T2D risk. Sensitivity and specificity to predict T2D provided an 671 
aROC of 0.58 [111]. During the last decade, large-scale GWAS have identified more than 400 672 
gene single nucleotide polymorphisms (SNPs) influencing T2D risk [112]. Most of these variants 673 
are widely shared within and between populations but have only a modest effect on individual 674 
predisposition in contrast to the alleles that drive rarer subtypes of diabetes. To an extent, 675 
combining these variants in a genetic score can predict an individual’s risk of developing T2D 676 
[112, 113].  677 
 678 
Nevertheless, there is a need to combine genetic and clinical information further to maximize 679 
risk prediction. In the most recent GWAS for T2D, the entire set of associated variants detected 680 
explained ~20% of the overall variation for disease risk in European populations [112]. Indeed, 681 
estimates of T2D heritability vary widely [114] around a median of 40%. Therefore, as genetics 682 
contribute to about half of the variation in risk for each individual, integration with accurate and 683 
robust measures of other contributing factors is required[115].  684 
 685 
Initial studies in 2008 constructed restricted-to-significant polygenic scores (rsPSs), i.e. scores 686 
composed of 16-18 variants known at the time to be at the extreme of a statistical distribution 687 
and weighted to reflect their respective effect size on the hyperglycemic trait [116-118]. Their 688 
predictive performance did not outweigh clinical risk factors for T2D. The predictive ability of 689 
an 18 SNP rsPS was tested in 2377 participants of the Framingham Offspring Study during 28 690 
years of follow-up. The aROC for incident diabetes, with the score adjusted for age and sex, was 691 
0.58. A clinical model that included age, sex, family history, BMI, fasting glucose, systolic blood 692 
pressure, HDL cholesterol, and triglyceride levels demonstrated an aROC of 0.90. Combining 693 
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both did not enhance aROC and resulted in risk reclassification of less than 4%. Nevertheless, 694 
those with rsPS >21 (~11% of the cohort) had 2.6 higher odds of developing T2D than did those 695 
with rsPG ≤15 (~25% of the cohort)[116]. RsPS of 18 SNPs and a clinical score tested in 4097 696 
participants from Scotland, demonstrated aROCs of 0.60 and 0.78, respectively, while combining 697 
both resulted in a slight increase in the aROC to 0.80 [117].  698 
 699 
Lyssenko et al. [118] examined a 16 SNP rsPS in 16000 Swedish and 2770 Finnish subjects 700 
followed for a median of 23.5 years. The score adjusted for age and sex predicted T2D incidence 701 
with an aROC of 0.62. A score system of clinical factors, namely age, sex, a family history of 702 
diabetes, BMI, blood pressure, triglycerides, FPG, provided an aROC of 0.74.  A combination of 703 
rsPS and clinical factors produced an aROC of 0.75 with reclassification of 9% and 20% of 704 
subjects from the Swedish and Finnish studies respectively, to a higher risk category. 705 
 706 
Although larger GWAS have identified novel loci significantly associated with T2D, 707 
improvements in genetic score performance have been more modest. An rsPS of 62 SNP in the 708 
Framingham Offspring Study [119] produced an aROC for T2D prediction of 0.72 while the 709 
aROC generated with scoring clinical variables was 0.90 and combining both produced an aROC 710 
of 0.91. Similar outcomes were reported in the Coronary Artery Risk Development in Young 711 
Adults [119].  712 
 713 
More recently, Mahajan et al. [112] generated a global extended polygenic score (gePSs) that 714 
included large numbers of significant subthreshold variants from T2D GWAS meta-analysis of 715 
almost 460000 European individuals (effective sample size ~158000). An optimized gePS 716 
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comprising 171249 variants was constructed with 5639 cases and 112307 controls from the UK 717 
Biobank, which was then used to predict T2D case-control status in separate sets of 13480 cases 718 
and 311390 controls. The aROC was 0.73 after adjusting for age and sex. 719 
 720 
Khera et al. [113] applied an analogous approach with a deeper gePS of almost 7 million variants 721 
that, after adjusting for age and sex, generated a similar aROC. Performance of gePS and risk 722 
estimates were also confirmed by the direct-to-consumer company 23andMe in their data set of 723 
1,479,116 individuals. In individuals from the UK Biobank in the top 2.5-5.0% of the gePS 724 
distribution had a threefold increased risk of T2D and tenfold increase compared to those in the 725 
bottom 2.5% [112].  A different approach to estimate genetic risk of T2D based on patterns of 726 
genetic association across diabetes-related quantitate traits (glycemic measures, insulin secretion 727 
and insulin resistance) [120-122] demonstrated that T2D risk variants impact disease 728 
predisposition. 729 
 730 
Although GWAS has provided insight into the potential of genetic risk profiling, its clinical 731 
applicability remains uncertain. While a potential role for common variant risk scores to 732 
predicting risk for T2D was suggested earlier, subsequent studies demonstrated their limited 733 
increase in performance over clinical models that can be generated from more readily accessible 734 
risk factors. The substantial polygenicity and small effect of most risk variants have major 735 
implications for precision medicine. Nonetheless, overcoming obstacles in translating genetics 736 










5. The 50g Glucose Challenge Test (GCT) 745 
 746 
Table 1 outlines the advantages and limitations of different screening tests. . The 50g glucose 747 
challenge test (GCT 1-h glucose), performed at any time without fasting, whereas the 748 
standardized 75g OGTT requires a 10-12 hour overnight fast. .  Both tests are characterized by 749 
decreased reproducibility [124, 125]. The 50g glucose challenge test (GCT) could, however, 750 
provide optimal accuracy, precision and convenience for identifying dysglycemia. 751 
 752 
5.1. The GCT in Screening for Gestational Diabetes Mellitus 753 
The GCT has long been used in a two-step screening process for the diagnosis of GDM [126], 754 
and was the standard screening approach for GDM until 2010 when both the International 755 
Association of the Diabetes and Pregnancy Study Groups (IADPSG) [127] and the ADA [128], 756 
recommended one-step testing using a 75g OGTT alone.  757 
 758 
The two-step approach involves a 50g GCT for initial screening during weeks 24-28 of gestation.  759 
A 50g glucose solution (without prior fasting) is ingested with a glucose determination 760 
performed 1-h later (GCT 1-h glucose).  If the GCT 1-h glucose level is ≥130 mg/dl (7.2 761 
mmol/L) or ≥ 140 mg/dl (7.8 mmol/L), a second test (either a 75g OGTT or 100g OGTT) is 762 
conducted to confirm the diagnosis of GDM.  The two-step approach is endorsed by the 763 
American College of Obstetrics and Gynecology [129] and is widely used in clinical practice.  764 
 765 
The stepwise screening approach with the GCT may reduce by over 50% the number of pregnant 766 
women requiring a follow-up OGTT [130].  Moreover, an elevated GCT 1-h has been associated 767 
with increased pregnancy and fetal complications [131].   In addition to its utility to detect GDM, 768 
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higher GCT 1-h glucose levels have also been associated with increased risk for long-term 769 
metabolic sequelae and CVD during and after the postpartum period [132-137],  increasing along 770 
the continuum of GCT 1-h glucose values even within the non-diagnostic glucose range  [132, 771 
135, 138, 139]. 772 
 773 
These findings suggest that the GCT is a good predictor for future risk of T2D after pregnancy 774 
and could be useful for screening in the non-pregnant, high-risk population.  The two-step GCT 775 
may maximize identifying high-risk individuals while limiting confirmatory testing.  776 
 777 
5.2. The GCT in Non-Pregnant Individuals 778 
Two studies have evaluated the GCT as a screening test for prediabetes or diabetes in the non-779 
pregnant population [140, 141]. The Screening for Impaired Glucose Tolerance (SIGT) study 780 
was conducted in 1573 subjects not known to have diabetes.  Participants were evaluated with 781 
measurements of HbA1c, random plasma and capillary glucose, a 75g OGTT (FPG and 1- and 2-782 
h PG [1-h and 2-h OGTT] levels). Using the OGTT as the diagnostic standard, 4.6% of SIGT 783 
participants were found to have undiagnosed diabetes and 18.7% had “high-risk” prediabetes 784 
[using WHO criteria; FPG 110-125 mg/dl (6.1-6.9 mmol/L) and/or 2-h OGTT glucose 140-199 785 
mg/dl (7.8-11.1 mmol/L), without diabetes]. The GCT 1-h glucose performed better than HbA1c 786 
in detecting either dysglycemia (“high-risk” prediabetes or diabetes; ROC: 0.82, GCT 1-h 787 
glucose vs 0.71, HbA1c, p<0.001) or diabetes (ROC: 0.90, GCT 1-h glucose vs 0.82, HbA1c, 788 
p=0.018), and similarly to FPG (ROC 0.83 dysglycemia; ROC 0.93 diabetes).  Of note, the 1-h 789 
OGTT glucose had ROCs of 0.88 for dysglycemia and 0.93 for diabetes – performing better than 790 
both the GCT 1-h glucose and the FPG. A GCT 1-h glucose cutoff of 160 mg/dl (8.9 mmol/L) 791 
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had a sensitivity of 82% and specificity of 81% for identifying diabetes and a sensitivity of 53% 792 
and specificity of 87% for identifying dysglycemia. A lower cut-off of 140 mg/dl (7.8 mmol/L) 793 
provided improved sensitivities of 92% and 77% for diabetes and dysglycemia, respectively, but 794 
reduced specificities of 63% and 72%, respectively.  795 
 796 
A subsequent study evaluated the GCT to screen for dysglycemia in the U.S. Veterans 797 
population [141]. Subjects recruited from VA primary care clinics underwent testing procedures 798 
similar to the SIGT study without measurement of 1-h OGTT glucose levels [140].  Among the 799 
1535 Veterans enrolled, 9.8% had previously undiagnosed diabetes and 21.6% found to have 800 
“high-risk” prediabetes by the OGTT, higher than in the SIGT study, reflecting greater average 801 
age, BMI, and prevalence of African-Americans. The GCT 1-h glucose accurately predicted both 802 
diabetes and dysglycemia with ROCs of 0.85 and 0.76, respectively, and performed better than 803 
the HbA1c (0.67 and 0.63; both p<0.05 compared to the GCT).  A GCT 1-h glucose threshold 804 
>140 mg/dl (7.8 mmol/L) had 87% sensitivity and 61% specificity for identifying diabetes. A 805 
higher cutoff of 160 mg/dl (8.9 mmol/L) had lower sensitivity of 76% but a higher specificity of 806 
79%.  807 
 808 
In summary, the GCT was an accurate screening test for diabetes as well as dysglycemia in two 809 
distinct cohorts.  Moreover, differences in age, sex, race, BMI, and other risk factors did not alter 810 
the performance of the GCT in either study [140, 141].  Whether the GCT 1-h glucose would 811 





5.3. Cost  Effectiveness  815 
In both the SIGT [140] and VA screening studies [141], the GCT was found to be cost-effective. 816 
In the SIGT study, a GCT 1-h glucose threshold >140 mg/dl (7.8 mmol/L) would identify 40% 817 
of the at-risk population requiring a follow-up OGTT for confirmatory diagnosis [140]. Among 818 
these individuals, 45% had either diabetes or prediabetes, which represented only 18% of the 819 
initial screening cohort; this approach, therefore, allowed targeted diagnostic testing in a subset 820 
of the at-risk population [140]., The cost of this stepwise approach was lower than standard 821 
screening recommendations and was deemed to be cost-effective [140, 141].  From a healthcare 822 
system perspective, GCT-based screening was projected to be cost-saving over 3 years compared 823 
to no screening, particularly in higher-risk individuals with greater age or BMI [144]. 824 
 825 
The 50g GCT may provide an alternative approach to screening as it can be conducted any time 826 
of the day without fasting, requires one hour during a routine health care visit and appears to be 827 
cost-effective, it. The 50g GCT is convenient and accurate – important features for improving 828 
screening and detection rates of prediabetes and diabetes.   829 
31 
 
6. The Shape of the Glucose Curve  830 
 831 
The desire to improve diabetes risk stratification has spurred a newfound interest in identifying 832 
reliable and accurate alternatives to standard FPG, 2-h PG, and HbA1c thresholds.  Although 833 
established thresholds are highly specific for diabetes, up to 30% of high-risk individuals may 834 
have values within the normal range. Furthermore, the predictive ability for diabetes risk may 835 
vary with age, race, ethnicity, and the incidence of diabetes in the population [55, 59, 145, 146]. 836 
The OGTT values are discrete, ordered determinations from an underlying, continuous process to 837 
assess an individual’s glucose regulation. Therefore, the glucose curve shape is an attractive 838 
candidate biomarker since it is obtained during a standard OGTT and can reflect an individual’s 839 
metabolic information, a predictor for screening dysglycemia, abnormal IR, and secretory state 840 
[147-150].  Differences in the shape of the glucose curve have been documented since the 1950s, 841 
coinciding with the concurrent use of the OGTT for the characterization of hyperglycemia [151].  842 
However, it is only recently that investigators considered using the glucose curve characteristics 843 
as a diagnostic and predictive tool. When applying novel methods, the entire curve is used as the 844 
basic unit of information instead of OGTT measurements at specific time points. 845 
6.1. Definition of glucose curve shape 846 
The shape of the glucose curve is defined by the pattern of rising and falling glucose 847 
concentrations after a fixed oral glucose load.  While some authors have described the glucose 848 
curve shape after a prolonged 3-hour OGTT [148], the conventional definition is to describe the 849 
curve shape after a standard 75gram 2-h OGTT [147, 149, 150].  The curve is obtained by either 850 
plotting glucose concentrations for at least 4 pre-specified time points (Figure 1A) or by using 3 851 
or more glucose concentrations for latent mixed class trajectory modeling [152] (Figure 1B).   852 
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6.2. Monophasic vs. Biphasic Shape 853 
In 2003, Tschritter et al. developed a simple index to classify the shape of the glucose curve into 854 
2 distinct shapes: a monophasic or biphasic curve [149].  Subsequent studies have conformed to 855 
this definition with minimal variation.  The monophasic curve is characterized by a gradual 856 
increase in glucose with a single peak and then falling, and the biphasic curve by a gradual rise 857 
in glucose to a peak, a gradual fall in glucose to a nadir and subsequent rise in glucose 858 
concentrations [149].  A third “unclassified” curve is sometimes described as a continuous rise in 859 
glucose without a definite peak, its diagnostic utility unclear as it is often omitted with greater 860 
attention given to the differences between monophasic and biphasic curve shapes [147-150].   861 
The rationale for the binary classification lies within its simplicity, ease of use, and association 862 
with pathological features of diabetes.  Defining the curves as monophasic vs. biphasic shapes do 863 
not require sophisticated mathematical modeling or equations and provide diagnostic and 864 
phenotypic insight into the individual’s glucose and insulin metabolic profile [147-150].  The 865 
monophasic compared to the biphasic curve has been associated with lower SI and decreased 866 
pancreatic β-cell function, measures that were validated against the hyperinsulinemia euglycemic 867 
clamp as well as mathematical equations from the OGTT [153-156]. A longitudinal model 868 
simulating progression to diabetes in a hypothetical subject [157] provided additional biological 869 
insight into the dynamic nature of the glucose curve shape [157].  This model showed that both 870 
β-cell failure and increasing IR were associated with a monophasic curve, a delay in the time to 871 
peak glucose and a rising glucose peak [157].  The model and clinical analysis agreed that the 872 
probability of a biphasic curve was low with progressive hyperglycemia with the shape of the 873 
curve not related to race, ethnicity or age.  874 
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Arguably, the most significant advantage of the curve shape is to improve early risk stratification 875 
in individuals with normal fasting and 2-h PG concentrations who might benefit from early 876 
intervention.  Several studies in children, adults, and pregnant women have examined the 877 
predictive ability of the monophasic curve shape for prediabetes and diabetes [158-161].  878 
Compared to the biphasic curve, the monophasic curve was a better predictor of prediabetes and 879 
diabetes in healthy adults after 3 years and in individuals at high-risk for both type 1 diabetes 880 
(T1D) and T2D after 8 years [158-160].   The curve shape has assessed the pathophysiologic 881 
evolution of diabetes.  Arslanian et al. evaluated the predictive capabilities of the shape of the 882 
curve for determining disease progression and treatment response in a randomized controlled 883 
trial of metformin, metformin + rosiglitazone and metformin + lifestyle, in youths with T2D 884 
[162].   In this study, the monophasic curve shape was associated with the highest treatment 885 
failure rates and the need for additional insulin therapy after an average of 2 years [162].   886 
However, not all studies have demonstrated improved diagnostic utility in using the simple 887 
binary shape classification [157, 163].  The monophasic shape is ubiquitous occurring in both 888 
high and low-risk individuals with NGT.  Overall, a significant limitation of the binary shape 889 
classification is that the discriminatory ability of the monophasic curve for diabetes is linked to 890 
its collinearity with overall glycemia, and the curve shape by itself does not account for the 891 
relative magnitude of the glucose excursions [70].  Therefore, the monophasic curve shape had 892 
poor reproducibility and low diagnostic sensitivity evaluated over time and failed to capture the 893 
biological heterogeneity in glucose curves or account for variabilities in measurement [158, 164].  894 
High false positive rates were observed in overweight and obese children and in post-895 
menopausal women for prediabetes across different racial and ethnic groups [157, 163-165].  896 
Heterogeneity in the glucose curve shape was observed across the spectrum of glucose tolerance 897 
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[155].  Furthermore, up to 20% of individuals did not fit into the binary monophasic vs. biphasic 898 
classification and the implication of having a monophasic curve during a 2-h test but a biphasic 899 
curve after a 3-h test are unknown [148].   900 
6.3. Modeling of the Glucose Curve 901 
Alternative approaches for delineating the heterogeneity of the glucose response curves have 902 
been developed. Modeling techniques are used to create shape indices that account for the 903 
complexity and biologic variability of glucose curve shapes with the premise that compound 904 
shapes have the lowest total glucose excursions and the highest β-cell function relative to SI [70, 905 
160, 161, 166].  For example, Alyass et al. investigated the performance of 14 OGTT glucose 906 
curve traits in T2D prediction and found that the highest predictive power was related to shapes 907 
that had the most significant total area under the glucose curve and the highest absolute 908 
concentration at the 1-h time point [167].  Curve fitting with functional principal component 909 
analysis was also used in women during the first trimester of pregnancy to forecast the 910 
development of GDM later in pregnancy [161].  This technique extracted common temporal 911 
characteristics of a set of curves and was superior to simple binary shape classification for 912 
predicting GDM.  However, the statistical expertise that is required for curve fitting and principal 913 
component analysis limits its clinical use.   914 
Recently, latent class trajectory analysis, another robust statistical tool often used in extensive 915 
epidemiological analyses of growth, showed promise for diagnosing and predicting diabetes and 916 
its complications (Figure 1B) [152, 168-170].  Latent class analysis was designed to capture 917 
subtle differences in metabolic phenotype over time with the additional advantage of providing 918 
probabilities for a class assignment.  Four main glucose curve classes (Class 1-4) were 919 
consistently observed that differed from each other in pathophysiological characteristics such as 920 
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glucose excursions and declining insulin sensitivity and secretion with time [152, 170].  Class 1 921 
was associated with the lowest diabetes risk and Class 4 with highest rates of diabetes 922 
progression and hyperglycemia at the 2-h time point.  Class 3 is notable because it is 923 
characterized by high 30-minute post glucose, despite normal fasting and 2-h glucose, and was 924 
associated with a ~4-fold increased risk for diabetes and higher all-cause mortality rate over an 925 
approximate 12 year period [169].   926 
The advantages of using the latent class analysis technique as an epidemiologic and potentially 927 
clinical tool include its ability to discern the certainty for latent class classification, its high 928 
reproducibility and the added value of documenting changes over time in a non-arbitrary manner.  929 
Further, although this modeling is most robust when utilizing five glucose time-points, reliable 930 
results can still be achieved with only three glucose time-points [171].  The integrated glucose 931 
response classifier model is available online for public use at https://steno.shinyapps.io/grc2h/.  932 
However, the application of this sophisticated model and its potential for changing screening and 933 
diagnostic paradigms remains to be determined.  934 
The shape of the glucose curve is a dynamic biomarker reflecting the cumulative effect of insulin 935 
sensitivity and response on glucose concentrations.  A more complex shape is associated with a 936 
lower risk for diabetes, but using the monophasic vs. biphasic binary classification has relatively 937 
low sensitivity.  Modeling patterns of change in shape over time could be a robust clinical or 938 
epidemiologic metabolic tool but would require conducting OGTTs with at least 4 glucose 939 
measurements and may increase the economic and personal patient burden associated with blood 940 
collection procedures and analysis that may limit its widespread clinical applicability. 941 
Prospective studies are warranted to evaluate the prognostic utility of OGTT-derived shape 942 
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indices or latent-class model derived sub-groups as promising tools for identifying high-risk 943 
subgroups and improve diabetes screening and risk stratification.  944 
7.  Continuous Glucose Monitoring and Glycemic Variability  945 
Novel Continuous Glucose Monitoring (CGM) devices [172-175] are increasingly replacing 946 
conventional self-monitoring of blood glucose (SMBG) [176, 177] with the principal advantages 947 
of capturing glucose fluctuations referred to as short-term glycemic variability (GV) and for 948 
detecting silent hyper- and hypoglycemic episodes [174, 178-180]. Therefore, CGM is a 949 
powerful tool to improve assessment of glucose homeostasis during insulin therapy [172, 173, 950 
181]. Extending its use to prediabetes may help identify different phenotypes of early 951 
dysglycemia (IFG and IGT).  952 
7.1. Insights from Continuous Glucose Monitoring Technology 953 
 7.1.1. The evolution of 24-h glucose profiles from normal glucose tolerance to 954 
advanced glycemic disorders 955 
7.1.1.1. Nondiabetic Individuals  956 
In 153 nondiabetic individuals (HbA1c< 5.7% [39 mmol/mol]) aged 7-80 years [182] wearing 957 
the Dexcom G6 system for approximately 10 days on an ambulatory basis, Shah et al established 958 
that the average 24-h glucose was 99 ± 7 mg/dl (5.5 +/- 0.39 mmol/L) and the within-individual 959 
coefficient of variation (% CV) for glucose was 17 ± 3%. In this study, glucose values below 54 960 
mg/dl (3.0 mmol/L) and above 180 mg/dl (10 mmol/L) were uncommon with the median time 961 
spent above 140 mg/dl (7.8 mmol/L) or below 70 mg/dl (3.9 mmol/L) being 30 or 15 minutes per 962 
day, respectively. Postprandial glucose excursions were not quantified and information on other 963 
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subtle glycemic disorders such as the presence or absence of the dawn phenomenon were not 964 
provided [183].   965 
7.1.2. Key stages from prediabetes to overt T2D 966 
7.1.2.1.The dawn phenomenon 967 
The dawn phenomenon corresponds to a rise in PG > 20 mg/dl (1.11 mmol/L) during the end of 968 
the nocturnal period in the absence of nutritional intake (fasting state). This is mainly due to the 969 
circadian variation in hepatic glucose production which starts to increase in the evening, reaches 970 
a peak towards the end of the overnight period before declining during the daytime until its late 971 
afternoon nadir [184]. Its main consequences include elevation of the early morning fasting 972 
blood glucose with or without an abnormally elevated and delayed post-breakfast glucose 973 
excursion referred to as the “extended dawn phenomenon” [184]. The latter is postulated to be 974 
due to an extended period of hepatic glucose production not encountered in non-diabetic subjects 975 
[185] complemented by intestinal hydrolysis of carbohydrates following breakfast. In those with 976 
normal metabolism, hepatic glucose overproduction is prevented by an increase in endogenous 977 
insulin and a decrease in glucagon secretion. The dawn phenomenon is evident when HbA1c 978 
levels range from 5.7 to 6.4% (39-46 mmol/mol), when postprandial glucose excursions and 979 
basal glucose exposure (nocturnal and interprandial glucose concentrations) remain within the 980 
normal range [186]. These observations suggest that the dawn phenomenon represents an early 981 
expression of dysglycemia (prediabetes) in the natural history of T2D[187]. Detection of the 982 
dawn phenomenon necessitates the use of CGM to demonstrate the magnitude of the difference 983 
between the nocturnal glucose nadir and the pre-breakfast glucose value.  984 
7.1.2.2. Post-meal hyperglycemia 985 
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When the HbA1c level exceeds 6.5% (46 mmol/mol), excess postprandial glucose elevations 986 
(average 2-h postprandial > 140 mg/dl [7.8 mmol/L]) are observed which usually remain isolated 987 
as long as HbA1c does not exceed 7.0% (53 mmol/mol) [186]. Post-meal hyperglycemia 988 
resulting from the extended dawn phenomenon is frequently combined with the dawn 989 
phenomenon representing the state of prediabetes that precedes overt T2D. The complete 990 
characterization (phenotyping) of this stage can also be best revealed by conducting CGM in 991 
those with HbA1c levels between 6.5 and 6.9% (48- 52 mmol/mol) (Figures 2 )[187].                                                            992 
7.1.2.3. Basal hyperglycemia 993 
When the HbA1c is 7% to 8% (53- 64 mmol/mol), postprandial and basal (fasting and 994 
interprandial) glucose contribute equally to overall hyperglycemia [188] whereas with a HbA1c  995 
level > 8% (64 mmol/mol), the basal component increases linearly while the postprandial 996 
contribution remains relatively constant approximating one percentage point of HbA1c [189]. 997 
Therefore, basal glucose becomes the major contributor to overall hyperglycemia in advanced 998 
T2D (Figure 2).  999 
7.2. Glycemic Variability for Detecting Prediabetes  1000 
The continuum of deteriorating glucose homeostasis is also associated with a progressive 1001 
increase in within-day GV expressed by % CV for glucose. The median % CV in non-insulin 1002 
treated individuals with HbA1c levels ranging from 6.4 to 7.0% (46 to 53 mmol/mol) and 7.1 to 1003 
8.6% (54 to 70 mmol/mol), are  18.6% and 23.7%, respectively, compared to a median % CV of 1004 
= 27.8% in insulin-treated T2D [190]. In contrast, the % CV in non-diabetic subjects is 1005 
approximately 17%, but fails to distinguish the early stages of dysglycemia. Although GV 1006 
increases from NGT to prediabetes, IFG and IGT [191], it is debated whether GV reflects the 1007 
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continuum from prediabetes to diabetes [191, 192]. Nevertheless, CGM appears to be valuable 1008 
for unraveling the early changes in overall glucose homeostasis in the natural history of the 1009 
disease.  1010 
8. 7.3. Classifying Dysglycemic States  1011 
In a study [193] involving 800 healthy subjects and individuals with prediabetes, CGM was 1012 
regarded as a key technology for assessing the variability of postprandial glycemic responses 1013 
while at the same time useful for improving diet quality and preventing T2D and its 1014 
complications. Postprandial glucose excursions can be accurately predicted by integrating 1015 
glucose responses into a machine-learning algorithm that takes into account several clinically 1016 
scalable biomarkers such as blood parameters, bioanthropometrics, physical activity and 1017 
microbiota. This study supports incorporating personalized precision nutrition to prevent 1018 
prediabetes and its potential conversion to overt diabetes [194]. Therefore, the CGM could 1019 
represent a key reference for implementing such strategies in the future based on detecting 1020 
different phenotypic glycemic patterns in their early stages and beyond.  1021 
7.4.Strengths and Weaknesses  1022 
The main advantage of CGM resides in the ability to determine interstitial glucose values at 1023 
frequent intervals thereby capturing infinite details of daily glucose homeostasis. However, 1024 
CGM systems have shortcomings. The glucose oxidase embedded in the biosensor oxidizes each 1025 
molecule of glucose with the electric current generated by the chemical reaction being 1026 
proportional to the glucose concentration in the interstitial fluid [195]. The slope of the linear 1027 
relationship between these two parameters corresponds to the biosensor sensitivity, the 1028 
assessment of which requires calibration of the device by aligning the interstitial glucose with a 1029 
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reference glucose value [196, 197].  However, these two values usually differ by approximately 1030 
10-20 mg/dl (0.55-1.11 mmol/L) [196-198], a difference that becomes crucial when glucose 1031 
concentrations are in the near-normal range [197, 198] encountered in the prediabetes state. 1032 
Another potential source of error is the lag time  approximating 10 to 15 minutes, especially 1033 
when measurements are made during periods of sudden and rapid changes in circulating glucose 1034 
[199].  1035 
In conclusion, an inexact relationship exists between glucose concentrations and interstitial 1036 
values recorded by CMG devices [199]. Consequently, CGM has not been approved for 1037 
detecting glucose intolerant states although this may become a reality in the future. Nonetheless, 1038 
CGM represents an important development to better understand the pathophysiology of 1039 
prediabetes, differentiate the different phenotypes of T2D in addition to aiding the clinician to 1040 
better manage each individual based on the different degrees and patterns of dysglycemia. 1041 
 1042 
8. Insulin Resistance and Insulin Secretion  1043 
IR and deterioration of β-cell function are fundamental to the initial development and 1044 
progression of impaired glucose regulation [200]. Alterations in these principal homeostatic 1045 
mechanisms are among the best predictors of the risk for T2D with several techniques developed 1046 
for in vivo assessment. 1047 
 1048 
8.1.  Insulin Sensitivity (SI) 1049 
8.1.1. Clamp technique  1050 
The euglycemic insulin clamp technique remains the gold standard for measurement of insulin 1051 
action in vivo [201]. The technique is accurate and, because it is based on the achievement of a 1052 
41 
 
steady-state condition, it can be combined with other methodologies (e.g., mathematical 1053 
modeling, tracer infusion, indirect calorimetry, arteriovenous catheterization) allowing 1054 
comprehensive evaluation of insulin action on glucose, lipids, and protein metabolism at the 1055 
whole body as well as tissue levels [202]. Collaborative efforts, such as the RISC (Relationship 1056 
between Insulin Sensitivity and Cardiovascular Disease) Study, have pooled euglycemic clamp 1057 
studies in 13 European countries to establish a prospective, observational study as well as 1058 
determine to what extent SI and β-cell function (estimated by mathematical modelling of an 1059 
OGTT (see below), could account for progression or regression of glucose intolerance. After 1060 
adjustment for family history of diabetes, age, waist-to-hip ratio, fasting and post-load glucose 1061 
levels,  IR was an independent predictor of progression from NGT to IGT [203].  Insulin 1062 
resistance determined by the euglycemic clamp was found to be a major risk factor for the 1063 
development of T2D in Pima Indians [204].  1064 
 1065 
8.1.2.  Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)  1066 
 Unlike the glucose clamp, which depends on steady-state conditions, the minimal model 1067 
approach uses dynamic data obtained with rapid intravenous injection of glucose. This is usually 1068 
applied in assessing SI during a FSIVGTT [205] or its more modern insulin-modified version. 1069 
Simplified, short sampling protocols have been developed to facilitate studying larger numbers 1070 
of subjects. The FSIVGTT can allow the estimation of other parameters of interest, e.g. glucose 1071 
effectiveness (Sg), i.e. the capacity of glucose to enhance its own cellular uptake and to suppress 1072 
endogenous glucose production and acute insulin response (AIR). The FSIVGTT was performed 1073 
in 1,230 Hispanic-Americans and African-Americans in the Insulin Resistance Atherosclerosis 1074 
Study (IRAS) Family Study [206]. After adjustment for confounding factors, SI was inversely 1075 
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associated with development of T2D (OR 0.53, 95% CI 0.39-0.73; p < 0.001). In the IRAS 1076 
Study, Sg was an independent risk factor for future diabetes in individuals with family history of 1077 
diabetes with similar results demonstrated independent of age, sex, race/ethnicity, glucose 1078 
tolerance, and adiposity [206]. Using the same technique, the development of T2D was found to 1079 
be preceded and predicted by defects in both insulin-dependent and insulin-independent glucose 1080 
uptake [207] Moreover, these defects were detected more than a decade before the diagnosis of 1081 
T2D when subjects were normoglycemic 1082 
8.1.3.  Oral Glucose Tolerance Test (OGTT)  1083 
Though accurate, the clamp technique and the FSIVGTT are labor intensive and, therefore, 1084 
difficult for use in the clinical setting or in large epidemiological studies. Alternatively, surrogate 1085 
measures of insulin secretion and SI have been derived from more commonly used diagnostic 1086 
procedures. From this perspective, the OGTT, the most frequently used method to assess glucose 1087 
tolerance, can offer a simple and more physiologic approach. Surrogate markers of insulin action 1088 
can be derived by concomitant plasma glucose, insulin and C-peptide measurements. The SI  1089 
index-Matsuda [ISI (Matsuda)] reflects a composite estimate of hepatic and muscle SI [208].The 1090 
Insulin Sensitivity Index (ISI) is defined as the ratio between PG clearance rate and mean plasma 1091 
insulin concentration [209]. These indexes correlate well with direct estimates of SI obtained 1092 
from glucose clamp studies. In a prospective study combining various cohorts [210], the ISI 1093 
index was best at predicting onset of T2D compared with other surrogate indexes derived from 1094 
dynamic tests, including the Stumvoll index [211], also derived from OGTT data. 1095 
 1096 
While all prior indexes are empirical, the OGTT-based IS (oral glucose insulin sensitivity 1097 
[OGIS]) index is based on a glucose-insulin model [212]. The OGIS correlates well with the 1098 
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clamp and in a Japanese study  reported the most sensitive index for assessment among 1099 
individuals with pre-hypertension/prediabetes [213].  1100 
 1101 
8.1.4. Simple Indexes of Insulin Action 1102 
HOMA was proposed by Matthews et al. [214] and remains the most widely used surrogate 1103 
measure of insulin action and β-cell function in clinical and epidemiologic studies. Based on a 1104 
structural model of the physiological feedback loop between the liver and the β-cell in the fasting 1105 
state, HOMA-IR provides an estimate of SI derived from FPG and insulin concentrations. 1106 
Recently, the HOMA model was expanded and improved equations (HOMA2) were provided to 1107 
compute HOMA2-IR as well as HOMA2-beta for β-cell function [215]. HOMA-IR is simple, 1108 
inexpensive and correlates well with SI determined by the euglycemic insulin clamp [216] or the 1109 
minimal model derived from the FSIVGTT [217].  1110 
 1111 
The ability of the HOMA model to predict the development of T2D has been evaluated in cross-1112 
sectional and cohort studies. Cross-sectional studies have shown strong associations between 1113 
HOMA-IR and HOMA-B and the prevalence of IGT and T2D in Japanese [218], Mexican-1114 
American and non-Hispanic white subjects [219]. HOMA-IR was a strong and independent 1115 
predictor of incident IGT in Japanese Americans over a 10-year follow-up [220] as well as the 1116 
10-year diabetes incidence in the Italian Bruneck Study [221]. In a study of combined 1117 
prospective data involving 3,574 participants including non-Hispanic white, African-American, 1118 
Hispanic American, and Mexican subjects followed between 5–8 years, HOMA-IR provided an 1119 




The Quantitative insulin sensitivity check index (QUICKI) is an empirically derived 1122 
mathematical transformation of fasting blood glucose and plasma insulin concentrations [222]. 1123 
Though QUICKI is based on a completely different rationale than HOMA, the two indexes are 1124 
related and have been suggested as simple, inexpensive, and minimally invasive surrogates for 1125 
measurements of SI that can be used in large epidemiological studies [223].  1126 
 1127 
8.2. Insulin Secretion 1128 
 1129 
Insulin secretion is tightly regulated through an integrated process encompassing finely tuned 1130 
feedback between the β-cell,  PG levels and other nutrients, SI, incretin hormones, 1131 
neuropeptides, and neuronal control. Disruption of this network and the reduction of β-cell mass 1132 
are responsible for abnormal insulin secretion in T2D. These abnormalities develop over an 1133 
extended period starting long before diabetes is diagnosed [224-227] most likely reflecting a 1134 
predisposing genetic background [228]. Early alterations in insulin secretion tend to be 1135 
qualitative rather than quantitative. Plasma insulin concentrations after an oral glucose load in 1136 
predisposed subjects may not differ from those obtained in individuals without predisposition but 1137 
when adjusted for prevalent plasma glucose levels and SI, a clear impairment of β-cell function 1138 
becomes apparent [229, 230]. In predisposed individuals, even among those with NGT, β-cell 1139 
function worsens with an increase in the 2-h PG levels [229, 230]. Several approaches for 1140 
assessing insulin secretion have been proposed defining β-cell function trajectory in the 1141 






8.2.1. Dynamic tests  1146 
The magnitude and kinetics of insulin secretion after a glucose challenge can be determined 1147 
during a hyperglycemic clamp [201], through minimal model analysis of the response to rapid 1148 
intravenous injection of glucose [205] or during an OGTT. With the hyperglycemic clamp, PG 1149 
concentrations are rapidly increased above baseline (usually > 125 mg/dl [6.9mmol/L]) and 1150 
glycemic levels maintained for variable periods allowing evaluation of first-and second-phase 1151 
insulin secretion. An estimation of the first-phase insulin secretion (AIR) is also provided by the 1152 
FSIVGTT. In the IRAS Study, after adjustment for confounding factors, AIR was inversely 1153 
associated with development of T2D (OR 0.22, 95% CI 0.14-0.34 per SD; both p < 0.001) [206]. 1154 
In addition, Osei and coworkers [231] showed that first-degree relatives of African-American 1155 
patients with T2D who progressed to either IGT and/or T2D had decreased mean acute first-1156 
phase insulin secretion before diagnosis. Data from the OGTT can be used to calculate the 1157 
Insulinogenic Index, i.e. the ratio between the increment in plasma glucose and insulin 1158 
concentrations 30 min after glucose ingestion. Among 319 subjects in whom an OGTT was 1159 
performed, the insulinogenic index adjusted for severity of IR was significantly worse in subjects 1160 
with IGT and combined IFG/IGT than subjects with IFG [61] , suggesting that subjects with IGT 1161 
and IFG may have different metabolic characteristics and different rates of progression to T2D. 1162 
These data strongly point to the loss of first-phase insulin secretion as a very early feature of β-1163 
cell dysfunction. First-phase insulin secretion plays an important role in priming the liver to 1164 
suppress endogenous glucose production in response to glucose or nutrient ingestion [232, 233] 1165 
and it has been identified as an independent predictor for the development of IGT [234] and T2D 1166 




All of the methods described have several limitations that preclude their routine clinical use as 1169 
diabetes risk predictors.  These include the complexity of the tests and the need to integrate 1170 
different control components that may affect the response of the β-cell to changes in glucose 1171 
levels (e.g., the action of incretins). Nevertheless, these measures are important research tools 1172 
further enhanced with mathematical models to describe the complex functions of dynamic 1173 
insulin secretion [237, 238]. Of relevance, mathematical modeling allows assessment of 1174 
parameters such as glucose sensitivity (i.e. the ability of the β-cell to respond incrementally with 1175 
an increase in glucose concentration), rate sensitivity (i.e. the response to the rate of change in 1176 
glucose levels), and the potentiation factor (i.e. the augmentation of β-cell response). These 1177 
parameters have a significant advantage  and =are derived from the PG and C-peptide response 1178 
to an OGTT as well as a standard mixed meal, allowing assessment of β-cell function under 1179 
physiologic conditions. In the RISC Study, glucose sensitivity was an independent predictor for 1180 
progression from NGT to IGT.  In particular, logistic regression revealed that baseline and 1181 
follow-up changes in β-cell glucose sensitivity and SI, rather than the classical clinical predictors 1182 
(adiposity, familial diabetes and glucose levels), were the key independent predictors of 1183 




8.2.2. Simple Indexes of β-cell Function  1188 
Different indexes based on fasting plasma insulin in relation to fasting blood glucose have been 1189 
proposed  as proxies of β-cell function. Among these, the HOMA-B index [214] and its more 1190 
recent revision HOMA2-B [215] are the best known and most commonly used. However, while 1191 
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HOMA-IR is considered a reliable index of SI, more controversy exists with respect to the 1192 
accuracy of HOMA-B as an assessment of pancreatic β-cell function[237]. Nonetheless, the 1193 
index has been used in epidemiologic studies such as the Women’s Health Initiative 1194 
Observational Study including 82,069 postmenopausal women showing that low HOMA-B was 1195 
independently and consistently associated (OR 0.57, 95% CI 0.51–0.63) with increased diabetes 1196 
risk after adjustment for confounding risk factors [240]. The main limitation of HOMA-B resides 1197 
in its non-comprehensive dynamic response after ingestion of a glucose challenge or a standard 1198 
meal. Further highlighting the utility of a simple index of β-cell function, Abdul-Ghani et. al. 1199 
[217] demonstrated that the insulin secretion/insulin resistance index derived from the OGTT 1200 
provides a superior method for predicting future development of T2D compared with the 1201 
diagnosis of IGT based on the 2-h PG concentration. 1202 
 1203 
8.2.3. Disposition Index 1204 
When jointly evaluated in the Women’s Health Initiative Observational Study, the relationship of 1205 
HOMA-IR and HOMA-B with diabetes risk appeared to be not only independent but also 1206 
additive implying a strong relationship between insulin secretion and SI. This relationship was 1207 
initially introduced by Kahn and co-workers [241] and a disposition index (DI, i.e., the product 1208 
of SI and insulin secretory response) has been used as a composite parameter for quantification 1209 
of glucose disposition in vivo. DI has been shown to predict conversion to diabetes [242] and 1210 






8.3. Parameters of insulin action/secretion and 1-hour  OGTT 1215 
 1216 
As described earlier, the 1-h PG <155 mg/dl (8.6 mmol/L) has been proposed as a potential 1217 
diagnostic parameter for identification of individuals at a high-risk of developing diabetes [68]. 1218 
The Genetic Physiopathology and Evolution (GENFIEV) Study, involving >1000 individuals at 1219 
risk of diabetes, found that NGT subjects with a 1-h PG >155 mg/dl (8.6 mmol/L)were more 1220 
insulin-resistant (HOMA-IR 2.68±1.93 vs. 2.14±1.22 mmol/L x µU/ml; p<0.001),had worse 1221 
insulin secretion (Insulinogenic Index: 0.052±0.030 vs. 0.092±0.17; p<0.001), and β-cell 1222 
performance (Disposition Index: 0.026±0.025 vs. 0.055±0.097; p<0.0001) compared to those 1223 
with 1-h PG ≤155 mg/dl (8.6 mmol/L) [85]. A reduction in first-phase insulin secretion 1224 
(1381±865 vs. 1721±1384 [pmol  m-2 BSA]  [mmoll-1min-1]-1; p<0.005) and lower β-cell 1225 
sensitivity were confirmed in NGT with 1-h PG >155 mg/dl (8.6 mmol/L) compared with NGT 1226 
with 1-h PG ≤155 mg/dl (8.6 mmol/L). Of interest, NGT individuals with 1-h >155 mg/dl (8.6 1227 
mmol/L) had a similar degree of SI as individuals with IGT though the latter had worse insulin 1228 
secretion. This observation is in keeping with the concept that β-cell failure, rather than IR, 1229 
accounts for the progressive deterioration of glucose homeostasis.  1230 
 1231 
Marini et al. [84] also found that NGT subjects with 1-h >155 mg/dl (8.6mmol/L) had an 1232 
impairment of SI similar to individuals with IGT. They also reported that subjects with 1-h PG 1233 
>155 mg/dl (8.6mmol/L), compared with NGT with 1-h PG ≤155 mg/dl (8.6mmol/L), had lower 1234 
AIR during intravenous glucose tolerance test (IVGTT) whereas no difference was apparent in 1235 
insulin secretion assessed by OGTT-derived indexes. Because of this apparent discrepancy, they 1236 
proposed that these individuals may retain a substantial incretin effect or, alternatively, a lower 1237 
sensitivity of the β-cell may already be present. Other smaller studies confirmed that 1-h PG 1238 
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>155 mg/dl (8.6mmol/L) is associated with alterations in β-cell function and SI [86, 244]. These 1239 
results lend further support to previous observations that impaired β-cell function is an early 1240 
defect in those at risk of developing T2D. In both the San Antonio Metabolism [229] and the 1241 
RISC [87] Studies, β-cell function was found to be already drastically impaired in NGT subjects 1242 
with the highest 2-h PG values. Nonetheless, in the RISC Study, NGT individuals with 1-h PG 1243 
>161 mg/dl (8.9 mmol/L) had greater IR, reduced β-cell glucose sensitivity, and reduced β-cell 1244 
rate sensitivity [87],features confirmed across ethnic groups. Thus, in Chinese subjects with 1245 
NGT subjects and 1-h PG ≥ 200 mg/dl (11.1 mmol/L), several metabolic abnormalities were 1246 
identified which seemed to be associated more with the impairment of early insulin release than 1247 
IR determined by HOMA [245]. 1248 
 1249 
In summary, though a standardized cut-off may still need to be identified, available evidence 1250 
strongly supports the role of impaired β-cell function that can be aggravated by concomitant IR 1251 
as a feature in NGT subjects with elevated 1-h PG levels. This provides support for the 1252 
pathophysiologic plausibility of the 1-h PG for early identification of individuals at risk of 1253 
developing T2D. 1254 
9. Metabolomics  1255 
Metabolomics is a promising tool for screening and diagnosis of T2D. Novel high-throughput 1256 
analytic chemistry methods enable the measurement of a large number of molecules comprising 1257 
the human metabolome. Mass spectrometry (MS) and nuclear magnetic resonance (NMR) 1258 
perform comprehensive metabolic profiling [246]. Gas chromatography (GC), isotope dilution 1259 
ultrahigh-performance liquid chromatography (LC) coupled to tandem mass spectrometry 1260 
(MS/MS) assays [247], as well as high-throughput NMR metabolomics can be used for absolute 1261 
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quantification [248]. Metabolomic profiling can be either non-targeted, by performing a 1262 
comprehensive analysis of all measurable molecular components in a given biological sample, or 1263 
targeted, by measuring a pre-selected metabolite panel [246]. Overall, metabolomic technologies 1264 
have made it possible to assess a large number of substrates representing different metabolic 1265 
pathways.  1266 
9.1. Metabolites for diagnosing prediabetes and diabetes  1267 
Several metabolites including amino acids, lipids and carbohydrates have potential as biomarkers 1268 
for T2D [249, 250].  1269 
9.1.1. Amino Acids 1270 
Several amino acids were consistently associated with the risk of developing T2D [249] with 1271 
extensive evidence demonstrating the association of BCAAs with obesity, IR and T2D [249].  1272 
Metabolomic analysis in a subset of individuals in the Framingham Heart Study demonstrated 1273 
that increased levels of BCAAs and aromatic amino acids (AAA) were associated with future 1274 
T2D [251]. Elevated levels of plasma BCAAs, including valine, leucine, and isoleucine, were 1275 
associated with IR and found to predict the onset of T2D [251]. The association of BCAAs with 1276 
incident diabetes and underlying metabolic abnormalities is generally stronger in Caucasian and 1277 
Hispanic populations [252].  1278 
The relationship between BCAA, IR and T2D is rather complex illustrated by a Mendelian 1279 
randomization study suggesting that IR may drive circulating BCAAs levels [253]. However, 1280 
despite BCAAs being highly correlated with BMI, insulin levels, HOMA-IR and T2D, these 1281 
were only modestly associated with IFG or combined IFG and IGT, and not with IGT [247]. This 1282 
suggested that different metabolites could pinpoint diverse metabolic imbalances within the same 1283 
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clinical condition. Furthermore, in the TwinsUK study, the branched-chain keto-acid metabolite, 1284 
3-methyl-2-oxovalerate was the strongest predictive biomarker for IFG after glucose in addition 1285 
to being moderately heritable [250]. In the Insulin Resistance Atherosclerosis Study (IRAS), 1286 
participants without diabetes with higher plasma BCAAs had lower insulin sensitivity, insulin 1287 
clearance rate and higher fasting insulin concentrations. The addition of BCAAs to models that 1288 
included traditional risk factors for T2D resulted in a trend to improve incident T2D–predictive 1289 
capacity: metabolic syndrome (aROC without BCAA 0.62 vs with BCAA 0.66), IFG (aROC 1290 
without BCAA 0.72 vs with BCAA 0.74), and BMI (aROC without BCAA 0.68 vs with BCAA 1291 
0.69), although these differences were not statistically significant [252].  1292 
9.1.2. Lipid metabolites  1293 
Free fatty acids and triglycerides have been associated with the risk of prediabetes and T2D. 1294 
Saturated fatty acids, including myristic (C14:0), palmitic (C16:0), stearic (C18:0) are increased 1295 
in both IFG and diabetes [254, 255]. Oleic acid (monounsaturated omega-9 acid), arachidonic 1296 
and linoleic acids (polyunsaturated omega-6 acids) are also higher in individuals with IFG and 1297 
diabetes [254, 255]. In a nested case-cohort study, the EPIC-InterAct, a fatty acid pattern score 1298 
with high relative concentrations of linoleic acid (C18:2n-6), stearic acid (C18:0), odd-chain 1299 
saturated fatty acids, very-long-chain saturated fatty acid (>20 carbons), and low relative 1300 
concentrations of linolenic acid (18:3n-6), palmitic acid, and long-chain monounsaturated fatty 1301 
acids, was associated with a reduced risk of developing T2D [256]. Plasma triacylglycerols with 1302 
lower carbon number and double-bond content have been associated with an increased risk of 1303 
T2D whereas those with higher carbon number and double bonds were associated with decreased 1304 
risk [257, 258]. Furthermore, triglycerides with odd-chain fatty acids were also inversely 1305 
associated with T2D after adjusting for total triglycerides [259].  1306 
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Acylcarnitines, produced in the mitochondria by the enzyme carnitine o-acetyltransferase, have 1307 
also been associated with higher risk of prediabetes and T2D [260, 261]. In the Nutrition and 1308 
Health of Aging Population in China (NHAPC) Study, a panel of acylcarnitines, especially long-1309 
chain acylcarnitines, was significantly associated with risk of developing T2D and was able to 1310 
improve the predictive ability for incident diabetes beyond conventional risk factors including 1311 
BMI and fasting glucose [262]. The addition of selected acylcarnitines to a model including 1312 
conventional risk factors improved the aROC for incident T2D from 0.73 to 0.89. 1313 
Different groups of phospholipids have been associated with distinct associations with the risk of 1314 
prediabetes and T2D [259, 263, 264]. Two plasma lipid profiles were associated with T2D after 1315 
3.8 years median follow-up in the PREDIMED trial. A profile including lysophospholipids, 1316 
phosphatidylcholine-plasmalogens, sphingomyelins, and cholesterol esters was associated with 1317 
lower risk of T2D while another comprising phosphatidylethanolamines, triglycerides and 1318 
diacylglycerols was associated with higher risk [259]. A composite of all lipid scores 1319 
significantly improved prediction of T2D beyond conventional risk factors although the effect 1320 
size was small (aROC 0.84 vs 0.83).  1321 
9.1.3. Carbohydrate metabolites 1322 
Other carbohydrate metabolites than glucose are altered in prediabetes and T2D including 1323 
mannose, fructose, and inositol [250, 258, 265-268].  1324 
In two independent cohort studies, mannose was associated with incident T2D after adjusting for 1325 
confounding factors including HbA1c and glucose [269]. Using a machine learning approach, 1326 
mannose was a robust metabolic marker to predict progression to T2D comparable to the 1-h PG 1327 
in the Botnia Prospective Study [77]. Using the optimal cutoff, mannose had a sensitivity of 1328 
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0.60, a specificity of 0.72 and an aROC of 0.70 for incident T2D. Mannose, alone or in 1329 
combination with other metabolites, also improved predictive performance when combined with 1330 
the 1-h PG [77].  1331 
9.2. Overview of metabolomics for diagnosing glycemic disorders 1332 
Metabolomics is not currently an established resource in routine clinical practice for diagnosing 1333 
glycemic disorders. The strongest evidence for the potential of individual metabolomics to 1334 
diagnose prediabetes and diabetes comes from a meta-analysis [249]. Due to the considerable 1335 
heterogeneity of reported lipid and carbohydrate metabolites, only studies examining the 1336 
prospective association between several amino acids and T2D were included. There was an 1337 
approximate 35% higher risk of T2D for isoleucine, leucine, valine or tyrosine and 26% for 1338 
phenylalanine with an inverse association of glycine and glutamine observed [249].  1339 
A metabolomics profile combining amino acids, lipids, carbohydrates and other metabolites 1340 
holds promise as a more effective screening tool for the early diagnoses of glycemic disorders 1341 
compared to isolated metabolites [270-272]. Fasting metabolomics, as an alternative to OGTT 1342 
for detecting IGT, identified a novel metabolite-based test in nondiabetic subjects participating in 1343 
the Relationship between Insulin Sensitivity and Cardiovascular Disease Study (RISC Study; 1344 
11.7% IGT) and the Diabetes Mellitus and Vascular Health Initiative (DMVhi) cohort in the 1345 
DEXLIFE project (11.8% IGT)  [271]. The addition of this metabolite panel to fasting glucose 1346 
improved the aROC curve for predicting IGT prediction from 0.70 to 0.82 in the RISC Study and 1347 
from 0.77 to 0.83 in the DMVhi [271]. 1348 
However, despite the considerable potential for metabolomics to define new biomarkers of 1349 
disease, only a few studies have reported sensitivity, specificity data or aROC curves thereby 1350 
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limiting translation into the clinical setting. Overall, metabolomics panels have low added 1351 
predictive value for T2D compared to prediction models using traditional risk factors (i.e., BMI, 1352 
metabolic syndrome, IFG), illustrated by modest increases in aROCs [77, 247, 249, 252, 273]. 1353 
Metabolomics, therefore, are not currently cost-effective and have limited value to assess risk for 1354 
or diagnose glycemic disorders. 1355 
10. Fructosamine, Glycated Albumin, and 1,5-Anhydroglucitol  1356 
Non-classical methods for assessing glycemic control include markers that evaluate shorter 1357 
periods of glucose exposure than HbA1c. These markers allow a more detailed understanding of 1358 
alterations in glycemic control, have potential use as screening or diagnostic tools for diabetes 1359 
and other glycemic disorders and provide additional information in assessing glycemic control in 1360 
specific populations (e.g. pediatrics or pregnancy). This section will review fructosamine, 1361 
glycated albumin, and 1,5-anhydroglucitol as alternative or added markers for detecting 1362 
glycemic disorders. 1363 
 1364 
10.1. Fructosamine 1365 
Glycation is a spontaneous non-enzymatic reaction, the product of the reaction of carbohydrate 1366 
moieties with the amino groups of proteins, DNA, and lipids, resulting in impaired biomolecules. 1367 
The glycation process is highly accelerated in diabetes and is associated with complications. 1368 
Serum fructosamine is a glycoprotein that results from the covalent attachment between a sugar 1369 
(such as glucose or fructose) to total serum proteins mostly, but not exclusively, albumin. This 1370 
will form an aldimine, a product of the Schiff reaction, which thereafter forms ketoamines 1371 
(proteins that contain fructosyl-lysine or fructosyl-(N-terminal) aminoacids). The term 1372 
fructosamine therefore reflects the linkage of ketoamines resulting in the glycation of serum 1373 
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proteins. The ketoamine can thereafter be converted to advanced glycation end products (AGEs) 1374 
contributing to organ damage. 1375 
 1376 
In contrast to intracellular hemoglobin, plasma proteins are more susceptible of being glycated 1377 
reflecting GV more accurately [274].  Because glycated proteins have a more rapid turnover than 1378 
HbA1c, which is dependent on erythrocyte turnover taking about 120 days, they are therefore not 1379 
affected by erythrocyte or hemoglobin characteristics providing relevant information on blood 1380 
glucose levels over the previous 2-4 weeks. Hence, they are short-term markers increasing in 1381 
states of high glucose concentrations [275, 276]. The reference range for fructosamine is 200-1382 
285 umol/L, which reflects the contribution of glycated albumin as well as all glycated proteins, 1383 
each with a different half-life and level of glycation. This biomarker can also be detected in 1384 
saliva being significantly higher in T2D and having a positive correlation with fasting, 1385 
postprandial plasma glucose, and HbA1c levels [277] . Because its measurement does not require 1386 
fasting, the use of fructosamine is convenient and cost-effective [278]. Furthermore, 1387 
fructosamine may be a valuable indicator to assess risk for T2D independent of baseline fasting 1388 
glucose and HbA1c measurements in individuals without diabetes [279, 280]. Fructosamine can 1389 
be affected by clinical conditions associated with altered protein metabolism or protein loss as in 1390 
the nephrotic syndrome as well as diminished protein synthesis (hepatic disease, cirrhosis), 1391 
thyroid disease and malnutrition [281, 282].   1392 
 1393 
Even though HbA1c is relevant for diagnosing and managing diabetes, several studies reinforce 1394 
its limitation in subjects affected by microvascular and macrovascular complications in which 1395 
short-term markers may play an important role [283]. The Atherosclerosis Risk in Communities 1396 
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(ARIC) study demonstrated that fructosamine was associated with risk of diabetes and those with 1397 
the highest levels had greater risk for retinopathy and albuminuria [284, 285]. In chronic kidney 1398 
disease (CKD), fructosamine increased with the progression of diabetic nephropathy, although it 1399 
is not clear if this was linked to early microangiopathic events [286]. On the other hand, Jung et 1400 
al. [287] suggested that the biomarker does not perform well in older adults with severe CKD. 1401 
Further studies are needed to confirm the effectiveness of fructosamine as a marker of 1402 
microvascular complications.  1403 
 1404 
Fructosamine performs better than HbA1c when monitoring glucose control during short-term 1405 
exercise [288] and appears to be more reliable when assessing patients requiring tighter glucose 1406 
control as in GDM and with increased post-prandial glucose excursions [289, 290]. A short-term 1407 
marker of glycemia is needed in GDM because HbA1c measurements are not reliable as glucose 1408 
and iron concentrations decrease while erythrocyte turnover increases [290, 291].  Fructosamine 1409 
is a preferred alternative because it can be obtained from a single random blood sample and does 1410 
not require  an OGTT [292]. However, fructosamine was insensitive for identifying GDM in 1411 
early pregnancy [293] . Therefore, fructosamine may be a good biomarker to predict neonatal 1412 
outcomes and maternal glycemia but additional studies are needed to establish suitable reference 1413 
ranges [293-297].  1414 
 1415 
In summary, fructosamine may provide a more precise estimation of GV and short-term 1416 
therapeutic efficacy than HbA1c and implemented in circumstances when HbA1c may not be 1417 




10.2. Glycated Albumin 1420 
Albumin constitutes about 60% of total blood protein content, present in concentrations of 35-50 1421 
g/L, and has independent relevance as a glycemic marker. Glycation of albumin in the presence 1422 
of hyperglycemia leads to structural alterations through spontaneous non-enzymatic Maillard 1423 
reactions [298, 299]. Further oxidation of these Amadori products can produce AGEs, thought to 1424 
be pathologic, as glycated albumin (GA) bound to AGE receptors (RAGEs) have considerable 1425 
immunogenic properties [299, 300] .   1426 
 1427 
Due to the shorter half-life of albumin than hemoglobin, GA measurements are representative of 1428 
a far shorter prior period of exposure to circulating glucose than HbA1c approximating 2-3 1429 
weeks, similar to fructosamine [282] .  Furthermore, albumin is approximately 10 times more 1430 
sensitive to glycation than hemoglobin [301].    1431 
 1432 
As GA is not affected by the same limitations as hemoglobin, it may be an acceptable alternative 1433 
biomarker of glycemic control when HbA1c is unreliable as in CKD, particularly during 1434 
hemodialysis [302].  It also seems to be a better predictor of cardiovascular complications and 1435 
risk of hospitalization or death in these patients when HbA1c is especially unreliable in the 1436 
presence of anemia or erythropoietin administration [303, 304].  1437 
  1438 
Similar to fructosamine, the use of GA is limited in pathological conditions affecting albumin 1439 
metabolism including nephrotic syndrome, hyperthyroidism, glucocorticoid or iron therapy, 1440 
malnutrition, and advanced liver disease [282, 305-307]. Another possible confounding factor is 1441 
the interference of BMI with GA measurements [307]. While GA may underestimate glycemic 1442 
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control in overweight/obese individuals, the discrepancy seems to attenuate progressively with 1443 
progression of prediabetes or  BMI above 30 kg/m2 [308, 309]. The negative correlation of GA 1444 
with obesity is possibly related to the contribution of obesity-associated chronic inflammation in 1445 
accelerating albumin catabolism [283].   1446 
 1447 
GA may have a role in the diagnosis of diabetes and prediabetes. While GA may detect 1448 
undiagnosed diabetes, it was not superior to HbA1c in population studies [277]. Nevertheless, 1449 
cut-off values have been established to diagnose diabetes mainly in Asian populations but 1450 
recently in Caucasian and Afro-American populations as well [310-312]. However, GA was not 1451 
considered to have adequate sensitivity to detect prediabetes and predict T2D [313].  1452 
 1453 
Combining GA and fasting glucose has been proposed to possess adequate sensitivity and 1454 
specificity to detect diabetes and prediabetes [314]. Furthermore, GA may be a better glycemic 1455 
marker than HbA1c to monitor women with GDM [315]. The earlier window of estimating 1456 
glycemic control with GA may be especially valuable for monitoring lifestyle or 1457 
pharmacological interventions to control diabetes [316] . The shorter half-life of albumin 1458 
suggests that changes in glucose levels can be confirmed in four weeks by monitoring GA as 1459 
opposed to waiting 12 weeks with HbA1c, thereby allowing for earlier therapeutic adjustments 1460 
[316, 317].  1461 
 1462 
GA has also been proposed as a marker of inflammation and has additional value to HbA1c 1463 
regarding assessment of β-cell secretory dysfunction, postprandial glucose excursions, unstable 1464 
fluctuating glycemia, hypoglycemic episodes as well as predicting outcomes in GDM [289, 308, 1465 
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317-321]. GA was shown to be associated particularly with perinatal complications in newborn 1466 
babies of mothers with GDM performing better than HbA1c as well as predicting birthweight 1467 
and large-for-date infants [322].  1468 
 1469 
Novel implications for GA in the pathological processes related to diabetes have been recently 1470 
proposed [323]. This highlighted the role of albumin as a carrier protein involved in the crosstalk 1471 
between organs related to overall control of insulin sensitivity. Indeed, circulating GA derived 1472 
from hyperglycemia seems to further impair intracellular insulin signaling in skeletal muscle and 1473 
adipose tissue [324, 325]. Studies have not been particularly productive seeking genetic 1474 
determinants of GA [326]. 1475 
 1476 
GA plays a role as an atherogenic factor in the development of complications. GA leads to the 1477 
irreversible potentiation of atherogenic, thrombogenic and inflammatory responses, exacerbating 1478 
cardiovascular risk, abolition of the anti-inflammatory effect of HDL-cholesterol, and the 1479 
antioxidant effect of circulating albumin itself [327-329]. In addition, glycation was shown to 1480 
render albumin cytotoxic for several cerebral and vascular cell types and also less effective in 1481 
preventing the aggregation of β-amyloid fibers suspected of contributing to the progression of 1482 
Alzheimer’s disease [330]. Of note, GA/HbA1c but not GA or HbA1c alone correlates with risk 1483 
of Alzheimer’s disease [331].  1484 
 1485 
In summary, GA is not only an alternative marker of glycemic control when HbA1c is unreliable 1486 
but also appears to be an independent risk factor for diabetes complications and further 1487 




10.3. 1,5- anhydroglucitol 1490 
1,5- anhydroglucitol (1,5-AG) is a non-traditional glycemic biomarker based on a non-glycation 1491 
mechanism in different research and clinical endeavors mainly related to glycemic disorders. 1,5-1492 
1,5-AG is a glucidic molecule, ubiquitous in many different food sources, is in a relatively stable 1493 
concentration based on food intake, intestinal absorption, glomerular filtration and tubular 1494 
reabsorption [332]. The tubular reabsorption of 1,5-AG, through co-transporter SGLT4, is 1495 
competitive with glucose [333]. In situations where the glucose concentration exceeds the renal 1496 
threshold approximating 180 mg/dl (10 mmol/L), glucose glomerular excretion is increased as is 1497 
its tubular reabsorption. In this situation, 1,5-AG usually filtered in the glomeruli is not 1498 
reabsorbed in the tubules, increasing its urinary excretion and decreasing plasma concentration. 1499 
In contrast with other biomarkers, including HbA1c, fructosamine and GA that increase directly 1500 
with hyperglycemia, the plasma concentration of 1,5-AG decreases. 1501 
 1502 
Earlier studies demonstrated that the plasma concentration of 1,5-AG could be a marker of 1503 
previous (1-2 weeks) exposure to hyperglycemia above the glucose renal threshold, reflecting 1504 
post-prandial hyperglycemic peaks [334, 335]. Automated and quantitative 1,5-AG 1505 
measurements can be performed using commercially available biochemical assay kits[336-338]. 1506 
FDA approved this marker for monitoring intermediate-term glycemic control in those with 1507 
diabetes and post-prandial hyperglycemia [339].  1508 
 1509 
In the ARIC study, the reference range for healthy individuals was 2.5 to 28.7 ug/mL [312]. 1510 
4.9% of previously considered healthy individuals had a 1,5-AG concentration <10 ug/mL, the 1511 
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cut-off for defining exposure to hyperglycemia, potentially representing a subset of the 1512 
population with higher post-prandial glycemic peaks. Published reference values in various 1513 
populations, while showing differences in the healthy reference range, do not alter 10 µg/mL as 1514 
the threshold for exposure to hyperglycemia [340]. Demographic differences in 1,5-AG 1515 
concentrations may be due to non-glycemic causes such as dietary or other determinants 1516 
including rate of glucose digestion,  enteric uptake and possibly genetic variants conditioning 1517 
these factors [340, 341]. 1518 
 1519 
1,5-AG was measured in studies of individuals with NGT,  isolated IFG and/or IGT and diabetes. 1520 
The combination of FPG and 1,5-AG was shown to exclude the diagnosis of diabetes when the 1521 
FPG was <100 mg/dl (5.6 mmol/L) and 1,5-AG > 15.9 μg/mL. Diabetes was diagnosed by either 1522 
a FPG ≥ 126 mg/dl (7.0 mmol/L) or serum 1,5-AG level ≤ 15.9 μg/mL with  an OGTT 1523 
performed if neither of these criteria were met. Using the aforementioned criteria, the sensitivity, 1524 
specificity, PPV, and NPV for the combination of FPG and 1,5-AG were 78.7%, 72.3%, 72.0%, 1525 
and 78.9%, respectively. When combining FPG and 1,5-AG employing a single sample, an 1526 
OGTT could be avoided in 75.8% of cases representing a more efficient process for screening 1527 
and diagnosing diabetes [342].  1528 
 1529 
A similar study in Asian Indians demonstrated that levels of 1,5-AG were progressively lower as 1530 
glucose intolerance progressed from normal to IGT to T2D [343]. Individuals without diabetes 1531 
and low levels of 1,5-AG (<10µg/mL) were at higher risk for developing diabetes. There was 1532 
also an association of low 1,5-AG with known risk factors for hyperglycemia [344]. The results 1533 
of screening with 1,5-AG may differ depending on whether post-prandial hyperglycemia or IFG 1534 
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is dominant [342]. In T2D, levels were lower in those with higher post-prandial glucose values 1535 
[343]. 1536 
 1537 
Prolonged exposure to hyperglycemia, measured by glycated biomarkers, leads to micro- and 1538 
macrovascular disease and is associated with greater morbidity and earlier mortality. Glycemic 1539 
excursions, which may be an independent factor for CVD, may not be reflected with HbA1c 1540 
[345]. However, 1,5-AG as a marker of short-term GV, has been associated with risk for CVD 1541 
[346]. In the ARIC study, a 1,5-AG threshold of 6 µg/mL, as opposed to concentrations > 10 1542 
µg/mL, i.e., in the non-diabetic range, significantly increased the risk of coronary heart disease, 1543 
heart failure, stroke and death [347]. In another study, low levels of 1,5-AG were associated with 1544 
microvascular events (new or worsening nephropathy or retinopathy) when Hazard Ratios 1545 
significantly increased with 1,5-AG values <10 µg/mL but there was no association with 1546 
macrovascular outcomes (cardiovascular death, non-fatal myocardial infarction and non-fatal 1547 
stroke) [348]. This contrasts with another study in  which low 1,5-AG levels were independently 1548 
associated with long-term cardiac mortality in an acute care setting even in patients with HbA1c 1549 
<7% (53 mmol/mol) [349]. 1550 
 1551 
1,5-AG levels do not appear to be influenced by mild or moderate renal dysfunction supporting 1552 
its role as a reliable glycemic marker in T2D with CKD [333]. Most studies with 1,5-AG have 1553 
been performed in diabetic populations[350] and as a marker to demonstrate the efficacy of 1554 
drugs prescribed in T2D except for SGLT2 inhibitors [351, 352]. 1,5-AG cannot be used in the 1555 
latter class since they promote glucose excretion and falsely reduce 1,5-AG levels. It should also 1556 
be noted that whereas fructosamine and GA have similar aROC values as HbA1c (0.83-0.87), 1557 
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1,5-AG is lower (0.70) [353]. The aROC for HbA1c, however, was found to be lower (0.78) in 1558 
conditions in which HbA1c is reportedly unreliable such as with hemodialysis [354],  in which 1559 
GA may be complementary [355].  1560 
 1561 
In conclusion, the clinical management of glycemic disorders is predicated on glucose control 1562 
and targeting other risk factors for preventing complications. Translating a continuous 1563 
biochemical variable into a marker that categorizes different glycemic states into various risk 1564 
groups could better inform decisions for selecting optimal therapies. The non-classical 1565 
biomarkers, fructosamine, GA and 1,5-AG, have adjunctive roles for glycemic assessment. 1566 
 1567 
 1568 
11. Conclusions 1569 
Figure 3 provides an overview of methods for detecting glycemic disorders considered in this 1570 
review. Several constitute important research tools and provide pathophysiologic and 1571 
mechanistic insight while not feasible for clinical consideration.  More sensitive, practical and 1572 
precise biomarkers are therefore required capable of predicting progression to dysglycemic states 1573 
at the earliest time point when the β-cell is still relatively functional and more likely responsive 1574 
to lifestyle modification. As FPG and HbA1c either alone or in combination may underdiagnose 1575 
a considerable number of high-risk individuals, the 2-h OGTT, rarely used in clinical practice, 1576 
remains the current gold standard for screening. Therefore, to improve upon current diagnostic 1577 
modalities, an alternative approach to the 2-h OGTT with greater practicality, simplicity and 1578 
cost-effectiveness is required.  1579 
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Combining biomarkers, including metabolites, may provide better precision for predicting 1580 
dysglycemia but would add considerable complexity and expense especially given the enormity 1581 
of the population at risk and therefore is not practical from a clinical perspective. Genetics, while 1582 
encouraging, has not evolved to a point where it can provide useful information in routine 1583 
practice. The GCT two-step screening may hold promise particularly given the ability to screen 1584 
without regard to fasting is important. However, a second stage confirmatory OGTT is required 1585 
for those failing the 50-gram screening which may therefore limit its widespread use. 1586 
Furthermore, the 1-h OGTT appears to be more sensitive to predict risk for T2D although a 1587 
comparative study would be worthwhile considering. 1588 
 1589 
Latent class analysis, development of CGM technology and measurements of IR and insulin 1590 
secretion have also been essential in furthering understanding the pathophysiology of 1591 
dysglycemic disorders. Although these modalities offer refined approaches to diagnosing and 1592 
characterizing glucose disorders, their complexity and expense make their general use 1593 
impractical beyond basic assessment of clinical and glycemic parameters. Other tools such as 1594 
fructosamine, GA and 1,5-AG are also informative and may be adjunctive or confirmatory to 1595 
glucose or HbA1c for detecting dysglycemia. 1596 
 1597 
Of the approaches considered in this review, the 1-h PG appears to be the most promising given 1598 
its greater sensitivity than FPG, HbA1c and the 2-h PG for detecting individuals at high-risk for 1599 
T2D. It furthermore appears to be superior to clinical risk factors and metabolomics with a 1-h 1600 
OGTT being more practical and cost-effective than the other methods described making it more 1601 
clinically acceptable. While data from the Finnish Diabetes Prevention Program support the cost-1602 
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effectiveness of the 1-h PG [70], a formal health economics evaluation would be important. 1603 
Finally, although a 1-h PG could replace the 2-h OGTT and HbA1c for detecting high-risk 1604 
individuals with prediabetes, a 2-h OGTT may still be necessary to diagnose T2D. A recent 1605 
meta-analysis suggests that the 1-h PG at a higher threshold than for detecting prediabetes could 1606 
serve this purpose [356]. A 1-h OGTT could eventually both detect prediabetes and diagnose 1607 
T2D in high-risk populations. 1608 
 1609 
Therefore, the 1-h PG has considerable potential as a biomarker for detecting glucose disorders if 1610 
confirmed by additional data including health economic analysis. Whether the 1-h OGTT is 1611 
superior to genetics and omics in providing greater precision for individualized treatment 1612 
requires further investigation. These methods will need to demonstrate substantial superiority to 1613 







Figure Legends 1621 
 1622 
Figure 1: Classification of glucose curve shape. (A) Simple analysis of curve shape: monophasic 1623 
(red), biphasic (green) and unclassified (purple) and (B)  Latent mixed class trajectory modeling 1624 
of curve shape: Class 1 (green), Class 2 (blue), Class 3 (orange), Class 4 (red) (adapted from 1625 






Figure 2: Illustration of the continuum in the deterioration of glucose homeostasis throughout 1630 
the natural history of T2D. 1631 
HbA1c =5.7 - 6.4% (39-46 mmol/mol): dawn phenomenon 1632 
HbA1c =6.5 - 6.9% (48-52 mmol/mol): dawn phenomenon plus postprandial hyperglycemia 1633 
HbA1c ≥ 7% (53 mmol/mol): progressive increment of basal hyperglycemia. 1634 
The respective contributions of postprandial and basal hyperglycemia can be depicted as follows: 1635 
postprandial  > basal when HbA1c = 7.0 -7.4% (53-57 mmol/mol), equal when HbA1c = 7.5 -1636 
7.9% (58-63 mmol/mol) and basal >postprandial when HbA1c  ≥ 8.0% (64 mmol/mol). Total 1637 
hyperglycemia is determined by the sum of the black (AUCbasal) and shaded areas 1638 
(AUCpostprandial). 1639 
 1640 
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Table 1: Current screening tests for prediabetes/diabetes – advantages and limitations 1705 
Screening test Advantages Limitations 
Fasting Plasma 
Glucose (FPG) 
Can be performed as a single 
blood draw. 
Requires overnight fast. 




Includes assessment of both 
fasting plasma glucose and the 2-
hour glucose after the oral 
glucose load. 
Allows assessment of the glucose 
response after an oral glucose 
challenge.  
Identifies more individuals with 
dysglycemia than the FPG or 
HbA1c. 
Requires overnight fast. 
Associated nausea in a subset of individuals after ingestion 
of 75g glucose load. 
Two-hour test duration. 
Sensitive to day-to-day differences due to diet and/or 
physical activity. 
Can vary according to time of day of testing. 
Reproducibility is not as good as the FPG or HbA1c.  
HbA1c Reflects integrated glucose levels 
over preceding 3 months. 
Convenient. 
Does not require fasting. 
Can be performed as a single 
blood draw. 
High reproducibility (precision). 
Less day-to-day perturbations 
during stress and illness. 
Standardized worldwide. 
Quality assurance in place. 
Less sensitive than the FPG and OGTT. 
Interpretation and accuracy can be affected by presence of 
hemoglobin variants (i.e., sickle cell trait), chronic renal 
failure, iron deficiency anemia, differences in red blood cell 
lifespan, and differences with age and race. 
May be high or low relative to underlying average glucose 
levels (accuracy – HbA1c “mismatches” as a reflection of 




Does not require fasting. 
Can be performed as a single 
blood draw. 
Often included in “metabolic 
profile” panels 
Very specific when elevated.  
Levels which (a) should be followed by confirmatory 
diagnostic tests, or (b) indicate a low likelihood of 













Table 2: Conditions Affecting HbA1c  1715 
1) Children and young adults 1716 
2) Pregnancy 1717 
3) New onset T1D and any other short duration hyperglycemia 1718 
4) Renal failure 1719 
5) HIV infection 1720 
6) Hemoglobinopathies 1721 
7) Anemia 1722 
8) Iron deficiency 1723 
9) Conditions that alter RBC lifespan, e.g. erythropoietin therapy, splenomegaly, 1724 
splenectomy, rheumatoid arthritis, antiviral therapy. 1725 


















Table 3. The Predictive Power of 1-h PG for T2D in Various Cohorts 1742 









































NA 0.84 75% 79% NA NA NA 
Abdul-
Ghani 









NA NA NA NA NA OR 3.4 (1.8, 6.4) 
without metabolic 
syndrome 





et al. 2009 
Botnia 
Study* 





0.795 NA NA NA NA OR 6.6 (3.03, 14.4) 




Centre in Chennai, 
India* 





0.689 66% 61% 19.5% 92.6% OR 3.04 (2.11, 
4.37) 
  




2603 4.94 160 
(≥8.9 
mmol/L) 
30% of total 
population 
0.80 75% 73% 15% 98% OR 8.0 
(5.5, 11.6) 




2386 23.5 151 
(≥8.4 
mmol/L) 
37% of total 
population 
0.70 62% 70% 33% 88% OR 3.8 
(3.1, 4.7) 
Fiorentino 




392 5.2 155 
(≥8.6 
mmol/L) 
19% of NGT 0.78§ 87%§ 64%§ 26%§ 97%§ OR 4.02 (1.06, 
15.26) 
Bergman M 
et al. 2016 
The Israel GOH 
Study* 
853 24 155 
(≥8.6 
mmol/L) 
22% of NGT 0.736 55% 77% NA NA OR 4.35 (2.50, 
7.73) 
Oka R et al 
2016 
Japanese Workers* 1445  4.5 163 
(≥9.0 
mmol/L) 
25% of total 
population 
0.88 NA NA NA NA HR 14.0  
(1.8, 106.2) 
Oh TJ et al. 
2017 
Korean Genome and 
Epidemiology 
Study (KoGES)* 
5703 12 144 
(≥8.0 
mmol/L) 
43% of total 
population 







1946  12.8  168 
(≥7.2 
mmol/L) 
NA 0.728 56% 79% NA NA HR 1.71 (1.60, 
1.82) 
Sai Prasanna Tertiary diabetes 1356 3.5 153 NA 0.716  64% 66% NA NA OR 1.026 (1.01, 
72 
 
















32% of NGT 0.698 NA NA NA NA HR 5.46 (3.14, 
9.50) 










32% of NGT 0.637 NA NA NA NA HR 3.40 (2.90, 
3.98) 







797 3 155 
(≥8.6 
mmol/L) 
22% of NGT 0.67 NA NA NA NA OR 2.74 (1.90, 
3.95) 
Saunajoki 
A.E. et al. 
2020  
Oulu45 population-
based cohort study* 
654 12 160 
(≥8.9 
mmol/L) 
34% 0.81 NA NA NA NA OR 9.26 
(5.6-15.0 
 1743 
*Definition of T2D based on FPG >126 mg/dl (7.0 mmol/L) and/or 2-h post-load >200 mg/dl (11.1 1744 
mmol/L). 1745 
**Botnia participants with incident T2D were diagnosed using patient records, follow-up FPG ≥126 1746 
mg/dl (7.0 mmol/L), 2-h post-load >200 mg/dl (≥11.1 mmol/l) or HbA1c ≥6.5% (48 mmol/mol), while 1747 
Malmö Preventive Project participants with incident T2D were diagnosed using patient records or follow-1748 
up FPG >126 mg/dL (7.0 mmol/L). 1749 
***Definition of T2D based on International Classification of Diseases (ICD) according to the relevant 1750 




Table 4. Predictive Power of FPG, 1-h PG, and 2-h PG for T2D  1753 
Publication Study Cohort FPG 1-h PG 2-h PG 
  Area under the ROC 
curve 
Area under the ROC 
curve  
Area under the ROC 
curve 
Abdul-Ghani MA et al. 
2007 
San Antonio Diabetes Prediction Model (SADPM)* 0.75 0.84 0.79 
Abdul-Ghani MA et al. 
2009 
Botnia Study* 0.672 0.795 0.688 
Priya M et al. 2013 Diabetes Specialties Centre in Chennai, India* 0.622 0.689 0.608 
Alyass A et al. 2015 Botnia Study** 0.65 0.80 0.71 
Alyass A et al. 2015 Malmo Preventive Project** 0.65 0.70 0.61 
Fiorentino VT et al. 
2015 
CATAMERI and EUGENE2* 0.73§ 0.78§ 0.73§ 
Bergman M et al. 2016 The Israel GOH Study* NA 0.736 0.707 
Oka R et al. 2016 Japanese Workers* 0.79 0.88 0.79 
Oh TJ et al. 2017 Korean Genome and Epidemiology Study (KoGES)* 0.61 0.74 0.63 
Paddock et al. 2017 Southwestern Native American (SWNA)* NA 0.728 0.706 
Sai Prasanna et al. 2017 Tertiary diabetes centre at Chennai, India* 0.593 0.716 0.618 
Pareek M et al. 2018 Malmo Preventive Project*** NA 0.698 0.553 
Pareek M et al. 2018 Malmo Preventive Project*** NA 0.637 0.511 
Manco M et al. 2019 Relationship between Insulin Sensitivity and Cardiovascular 
Risk (RISC)* 
0.71 0.67 0.65 
Saunajoki A.E. et al. 
2020  
Oulu45 population-based cohort study* 0.71 0.81 0.72 
 1754 
*Definition of type 2 diabetes based on fasting plasma glucose (FPG) >126 mg/dl (7.0 mmol/L) and/or 2-h post-load >200 mg/dl (11.1 mmol/L). 1755 
**Botnia participants with incident type 2 diabetes were diagnosed using patient records, follow-up FPG ≥126 mg/dl (7.0 mmol/L), 2-h post-load 1756 
>200 mg/dl (≥11.1 mmol/L) or HbA1c ≥6.5% (48 mmol/mol), while MPP participants with incident type 2 diabetes were diagnosed using patient 1757 
records or follow-up FPG >126 mg/dl (7.0 mmol/L). 1758 
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